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Abstract. 
This thesis describes how the principles of rational drug design have been used in the 
design of ligands for two proteins of therapeutic interest: elastase and factor XIII. In 
the case of elastase, X-ray crystallography has been used to visualise the interaction 
between the protein and each ligand. Attempts have been made to purify factor XIII 
for crystallisation and computer modelling has been used to investigate ligand 
binding. 
Elastase is a globular protein of 240 amino acids. It is produced in the pancreas as 
well as by neutrophils, granulocytes and leukocytes and plays a role in digestion and 
inflammation. It is a serine protease, depending for its mechanism on a catalytic 
triad of serine, histidine and aspartic acid in the active site. The over-activity of 
neutrophil elastase in the lung is implicated in emphysema and cystic fibrosis. 
Elastase also has a role in inflammatory diseases including rheumatoid arthritis and 
glomerulonephritis. Pharmacological inhibitors of the enzyme are therefore of 
considerable interest. 
Elastase is irreversibly inhibited by compounds incorporating a -1actam ring and 
this thesis describes structural studies on three classes of -1actam inhibitor. The 
mechanism of inhibition begins with nucleophilic attack by the catalytic serine on the 
carbonyl which is at position 2 of all the 3-1actams. In all cases this results in the 
opening of the ring between position one and two and the departure of the position 
four substituents. X-ray crystal structures and mass spectra obtained of elastase in 
complex with the ligands described the bound products of the reaction. -lactams 
having geminal diethyl groups at position 3 of the ring were proven to react by a 
different mechanism to those with a hydroxy ethyl at position 3. Hydroxy ethyl 
ligands are proposed to result in a more stable bound product. A ligand which had an 
ethyl group attached by a double bond at position 3 was found to be hydrolysed by 
the enzyme to give a breakdown product which remains non-covalently bound in the 
active site. A crystal structure of the non-covalently bound product was determined. 
The determination of 3-D structures of elastase with gold triethylphosphine and 
perrhenate is also reported. Gold triethylphosphine was found to have two 
alternative binding modes: to nitrogen N8 and NE of histidine 75, while perrhenate 
was shown to bind snugly into the S 1 binding site. 
Factor Xffl is the last enzyme in the blood coagulation cascade, stabilising blood 
clots by cross-linking fibrin. It is a transglutaminase, linking a lysine from one 
peptide substrate to a glutamine from the other via E(y-glutamyl)lySyl isopeptide 
bonds. In plasma, factor XIII exists in the inactive form as a heterotetramer, having 
two A subunits and two B subunits. Upon activation the two B subunits fall away 
and the A-A dimer performs the catalysis. The activation process also involves an 
unknown conformational change and thrombin cleavage which allows the departure 
of an activation peptide. Attempts made to purify the active form of the enzyme for 
crystallisation are described. A crystal structure of the inactive form of factor XIII 
has been used as the basis for computer modelling of the interaction of peptide 
ligands and the active form of the enzyme. Results of computer modelling of two 
peptide ligands with factor XIII are reported and a structure-activity hypothesis is 
presented. 
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Iv 
Where is the music? You can find it at many levels - in the vibrating strings, the trip 
of the hammers, the fingers striking the keys, the black marks of the paper, or the 
nerve impulses produced in the player's brain. But all of these are just codes; the 
reality of music is the shimmering, beautiful, invisible form that haunts our memories 
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Chapter 1: Introduction. 
This thesis describes how the principles of rational drug design have been used in the 
design of ligands for two proteins of therapeutic interest: elastase and factor XIII. In 
the case of elastase, X-ray crystallography has been used to visualise the interaction 
between the protein and each ligand. 
1.1 Elastase 
1.1.1 Elastase as a serine protease 
Elastase is a globular protein of 240 amino acids. The elastase chain is composed of 
two distinct halves which lie in intimate contact and which are joined covalently in 
the vicinity of residue 125 where the single polypeptide chain passes from one half to 
the other (see figure 1.1). Hydrogen bonds and hydrophobic interactions in the 
contact region hold together these two halves, which both participate in forming the 
catalytic site on the enzymes's surface. The molecule is further stabilised by two 
surface "transmolecular straps" (Sawyer et a!, 1971) formed by the N-terminal 
region and C-terminal a-helical "tail" which fold over from opposite sides of the 
molecule to make various favourable contacts and non-covalent bonds with the 
surfaces of the C-terminal and N-terminal halves of the molecule, respectively (see 
figure 1.2). 
Within each half of the elastase molecule the chain is folded into a series of large 
loops, in such a way that the chain runs antiparallel to neighbouring regions in the 
sequence (see fig 1.1). In each half of the molecule there are six antiparallel chains 
of irregular -pleated sheet and in each half the sheet curves round to form a 
cylinder. These "cylinders" are orientated approximately at right angles to one 
another. The cylinders are lined with aliphatic side chains. These hydrophobic cores 
must contribute substantially to the initial formation and subsequent stability of the 
folded enzyme (Sawyer et at, 1978). Elastase has four disulphide bridges (see fig 
1.1) which are involved in stabilising the cylinders and which are homologous to 
those in trypsin and chymotrypsin (Sawyer et a!, 1978). Although the two halves of 
the molecule adopt similar conformations, they are generated by two quite different 
Q i 
TA 
Figure 1.1: Diagramatic representation of the elastase fold (after Shotton and Watson, 
1970) showing the six antiparallel regions. The four disulphide bridges are indicated 
thus: (Diagram after Shotton and Watson. 1970). The chain is coloured 
blue to red from N-terminus to C-terminus. The sequence is shown below. 
\' 16 
R64 
EAQRNSWPSQ ISLQYRSGSS WAHTCGGTLI RQNWVMTAAH 
CVDRELTFRV VVGEHNLNQN DGTEQYVGVQ KIVVHPYWNT 
DDVAAGYD IA LLRLAQSVTL NSYVQLGVLP BAGTILANNS 
PCYITGWGLT RTNGQLAQTL QQAYLPTVDY AICSSSSYWG 
STVKNSMVCA GGDGVRSGCQ GDGGPLHCL VNGQYAVHGV 
TSFVSRLGCN VTRKPTVFTR VSAYISWINN VIASN 
The catalytic triad re idues are highlighted ii i their respective colours. 
Figure 1.2: Ribbon diagram of clastase coloured blue to red from N-terminus 
to C-terminus. The active site residues are in ball and stick representation: 
serine 203 in yellow: histidinc 60 in blue and aspartic acid 10 in green. 
The molecule can he seen to be orientated into two distinct halves with the 
chain passing from one side to the other between residue 122 and 132 (narrow 
green section). The N-terminal region and the C-terminal alpha-helical "tail' 
can each be seen to fold over the opposite half of the molecule forming the 
transmolecular 'straps". 
3 
stretches of polypeptide chain and so cannot be accounted for by gene duplication 
(Shotton and Watson, 1970). 
Elastase is a serine protease, and thus relies for its activity upon a catalytic triad of 
serine, histidine and aspartic acid in the active site. The aspartic acid side chain 
forms a hydrogen bond with the histidine N8 to facilitate the NE in removing the 
proton from the serine. The carbonyl carbon of the substrate undergoes nucleophilic 
attack by the serine hydroxyl group and a tetrahedral intermediate is formed (figure 
1.3). Collapse of the tetrahedral intermediate to form an acyl enzyme releases the 
product amine. The addition of water hydrolyses the acyl enzyme releasing the 
product acid and regenerating the active enzyme (Edwards and Veale, 1997) (see 
figure 1.3). This family of enzymes also includes trypsin and chymotrypsin. 
Trypsin, chymotrypsin and elastase share about 40% sequence identity (Shotton and 
Hartley, 1970) and X-ray crystallography reveals very similar structures, the 
common backbone atoms deviating by only I  approximately (Cohen et al, 1981). 
The three enzymes differ mainly in their specificities which depend on the nature of 
the residues lining the active site: in chymotrypsin, the bulky aromatic side chain of 
the preferred Phe, Trp, or Tyr residue that contributes the carbonyl group of the 
scissile peptide, fits snugly into a slit-like hydrophobic pocket located near the 
catalytic groups. Trypsin is similar to chymotrypsin except that it has an Asp at the 
back of the binding pocket to form ion pairs with its preferred residues, Arg or Lys. 
The binding pocket of elastase is largely occluded by Val and Thr so it specifically 
cleaves peptide bonds after small neutral residues, particularly Ala (Shotton and 
Watson, 1970). Elastase has the ability to cleave the most important connective 
tissue, elastin (Bode et a!, 1989). Elastin is a hydrophobic component of the 
extracellular matrix of skin, lung and large arteries (Bray & Anderson, 1991) and 
has the unique property of elastic recoil (Bode et al, 1989). Elastase therefore has a 
role in digestion. It is stored as an inactive zymogen in the pancreas and is secreted 
into the intestines where it becomes activated by trypsin in order to digest proteins 
(Bode et a!, 1989). 
Elastase is also essential for cells that migrate through connective tissue. Neutrophils 
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Figure 1.3: generalised mechanism of serine proteases. 
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secrete it for this purpose and for the destruction of foreign bacterial invaders which 
do not contain elastin (Bode et a!, 1989). It is the elastase released by neutrophils 
(Human Leukocyte Elastase [HLE]) that is implicated in various disease pathologies 
as discussed in the following section. 
1.1.2 Elastase as a medical target - role in inflammation 
Various insults to the body can give rise to the inflammatory response: infection, 
traumatic injury (including a surgical wound), a burn injury, or pancreatitis. The 
body's initial response to the insult is to induce a proinflammatory state. Cytokines 
and platelet-activating factor are released. These mediators have multiple 
overlapping effects and together these effects create an elaborate web of reactions 
designed to limit new damage and ameliorate whatever damage has already occurred 
(Fein et al, 1997). The inflammatory response has several stages (Fein et a!, 1997): 
• Recognition of microbial contamination or tissue injury 
• Release of signalling molecules 
• Recruitment of cellular effectors 
• Destruction of invading microbes and metabolism of injured tissue 
• Restoration of tissue integrity (wound healing). 
Acute inflammation induces substantial tissue injury. 	This occurs through 
recruitment of a large circulating pool of neutrophils, the primary functional effectors 
of inflammation. Neutrophil pathways for tissue injury and microbial killing include 
an NADPH oxidase that generates reactive oxygen species and enzymes capable of 
digesting basement and interstitial proteins facilitating directed migration and 
allowing for digestion of injured tissue (Fein et a!, 1997). 
Effects of proteinases released by inflammatory cells (Bray and Anderson, 1991): 
• Degrade extracellular matrix 
• Degrade tissue debris and microorganisms 
• Facilitate the migration of inflammatory cells across vessel walls and through 
tissues 
• Inactivate proteinase inhibitors 
• Activate and inactivate cytokines and mediators of inflammation 
• Increase microvascular and epithelial permeability 
• Modify proteins involved in clotting and thrombolysis 
• Activate inflammatory and immune cells 
These enzymes include elastase, which can also degrade a variety of functionally 
important molecules found at sites of inflammation including immunoglobulins and 
intermediates of the kinin, complement, fibrinolytic and clotting cascades (Fein et a!, 
1997). 
1.1.2.1 Cystic Fibrosis (CF) 
Cystic fibrosis is the most common lethal inherited disease among Caucasians. A 
mutation in a chloride channel causes abnormal electrolyte concentrations and 
production of very viscid bronchial secretions. This leads to mucocilliary 
disfunction and lung damage results from serial infections. Staphylococcus aureus is 
the first to colonise the CF lung followed by Haemophilus influenzae and 
Pseudornonas aeruginosa. The unique environment of the CF lung elicits a change 
in the growth of P. aeruginosa from normal to a mucoid form, heralding death in 
these patients. The organisms are thought to grow in microcolonies embedded in a 
Ca2tdependent mucoid alginate gel that blocks the airways. The gel protects the 
organisms from antibiotics and host defences. Faced with this large and persistent 
target, frustrated neutrophils release large amounts of elastase which is a major cause 
of lung damage in these patients (Govan and Nelson, 1993). 
1.1.2.2 Emphysema 
Emphysema is a lung disease in which the alveoli are abnormally enlarged. It results 
in inadequate oxygenation, disability and frequently death (Massaro and Massaro, 
1997). Emphysema can be produced in experimental animals with elastases, but not 
with other proteinases that cannot degrade elastin (Massaro and Massaro, 1997). 
Smokers are particularly susceptible to emphysema because the smoke causes 
oxidation of the active site methionine of the a 1 -proteinase inhibitor (Matsuse et al, 
7 
1995). This pathology has been corroborated by Hautamaki et a! (1997) who 
subjected macrophage deficient mice to cigarette smoke. In contrast to wild-type 
mice they did not develop emphysema in response to long-term exposure to cigarette 
smoke. This work implicates macrophage elastase as being sufficient for the 
development of emphysema that results from chronic inhalation of cigarette smoke. 
Fujie et a! (1999) observed that administration of an elastase inhibitor abolished the 
induction of emphysema in hamsters by intratracheally instilled elastase. This 
confirms the role of elastase in emphysema as well as giving hope of an effective 
drug for the condition. 
1.1.2.3 Rheumatoid Arthritis (RA) 
Rheumatoid arthritis is characterised by inflammation and swelling of the joints. 
Momohara et al (1997) measured gelatinolytic activity and polymorphonuclear 
leukocyte (PMN) elastase in articular cartilage and synovia from 8 patients with RA 
undergoing total knee replacement. Gelatinolytic activity was shown to be mainly 
due to the elastase and found to be highest in cartilage and synovia in RA joints. The 
levels of PMN elastase/proteinase inhibitor complex (EIC) were measured in the 
blood and synovial fluid of 170 patients with rheumatoid inflammation using 
immunoassay. The EIC levels in plasma of RA patients were significantly higher 
than those in gout and osteoarthritis, and the EIC levels increases according to the 
stage of articular cartilage destruction. Moreover the EIC levels in synovial fluid of 
RA patients were higher compared to those of osteoarthritis patients. The activity of 
PMN elastase was elevated in destructive joints of rheumatoid inflammation. With 
the progression of articular cartilage destruction, ETC levels in plasma of rheumatoid 
inflammation patients increased as well. Taken together this suggests that PMN 
elastase may play a significant role in RA disease. 
1.1.2.4 Atherosclerosis 
Atherosclerosis is a chronic disease of the arteries characterised by endothelial 
injury, the accumulation of lipids and fibrous tissue in plaques and the thickening 
and hardening of the vessel walls (Alexander et a!, 2000). Degradation of the elastic 
fibres of the arteries (elastin) by elastase has been implicated in the pathology of this 
disease (Olsson, 1987). Mohacsi et at, (1996) report that the activity of porcine 
pancreatic elastase is more effectively neutralised by the plasma of healthy subjects 
than by that of atherosclerotic subjects. This suggests diminished antiprotease 
activity in the sera of atherosclerosis patients. Blann et al (1996) measured 
neutrophil elastase, percutaneous oxygen and two markers of endothelial cell damage 
in blood from periferal atherosclerosis and normal controls. Patients had more cell 
damage and higher elastase but lower oxygen levels. Cell damage and percutaneous 
oxygen were inversely correlated. These results support the hypothesis that elastase 
from activated neutrophils relates to endothelial cell damage. This may contribute to 
hypoxia and may result in the deterioration of clinically assessed atherosclerosis. 
1.1.2.5 Glomerulonephritis 
Glomerulonephritis is inflammation of the filtering units of the kidneys, the 
glomeruli and associated cell infiltration of the interstitium of the renal medulla. 
This means that lymphocytes are found in the tubules of the medulla which leads to 
destruction of the nephrons and shrinking of the kidneys. Cellular crescents are often 
seen in Bowmans' capsules "crescentic glomerulonephritis" (Wardle, 1996). Oda et 
al (1997) used antibodies to localise neutrophils and neutrophil elastase in renal 
tissues. In normal controls neutrophil infiltration was scarce and NB was localised in 
neutrophil cytoplasm. In crescentic glomerulonephritis neutrophils were abundant 
and neutrophil elastase appeared extracellularly as well as in the urine of patients. 
Their results indicate that neutrophil elastase plays a significant role in renal tissue 
damage, especially in the formation of lesions in crescentic glomerulonephritis. 
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1.1.2.6 Septic Shock 
The release of proinflammatory mediators is a normal part of the body's response to 
infection or trauma. These mediators help to recruit neutrophils, I cells, B cells, 
platelets and coagulation factors to the site of injury or infection. Eventually they 
will stimulate a compensatory systemic anti-inflammatory response, which normally 
quickly down regulates the initial proinflammatory response. But in some patients, 
regulation of the inflammatory response is lost and a massive systemic reaction 
ensues. Many patients who suffer from persistent inflammation die rapidly of shock 
unless the body's compensatory anti-inflammatory mechanisms are able to bring the 
inflammation under control. In some patients however the compensatory reaction 
may be as excessive as the proinflammatory response and immune suppression may 
ensue. This is immunologic dissonance and unless the body can recover its balance, 
organ failure and death will occur (Fein et al, 1997). 
Neutrophils are involved in the dysregulation of the inflammatory response: 
hypochlorous acid, the main oxidant produced by neutrophils has little ability to 
damage normal tissues (Fein et a!, 1997). Instead neutophil extracellular proteases 
may be potent mediators of tissue injury. Of the neutrophil proteases, elastase has 
the greatest potential to cause tissue injury: not only is it present in the highest 
concentrations but it has almost no substrate specificity in the neutral pH range (Fein 
et al, 1997). In sepsis the main inhibitor of polymorphonuclear lymphocyte (PMN) 
elastase, a 1 -proteinase inhibitor, is susceptable to degradation by proteinases. In its 
absence elastase may easily inactivate and degrade the principal inhibitors of the 
clotting, fibrinolytic and complement cascades, resulting in life threatening 
consumption of these important hemostatic factors. Elastase may also degrade the 
main cysteine proteinase inhibitors, enhancing the potency of proteinases released 
from macrophages and monocytes. Human studies have reported a close correlation 
between the release of PMN elastase and the severity of organ injury, the occurrence 
of multiple organ failure and mortality (Fein et al, 1997). Thus when normal 
compensatory or regulatory mechanisms are damaged, dysregulation of the normal 
inflammatory response may lead to elastase-induced tissue injury. 
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1.1.3 Elastase and medical imaging 
As has been discussed, elastase is implicated in a number of diverse pathological 
conditions. Synthetic inhibitors that can regulate the in vivo activity of elastase will 
therefore have many disparate therapeutic applications. Consequently any novel 
inhibitor is of interest in a therapeutic context. However a major area of interest is 
the developement of in-vivo diagnostic imaging agents. One such technique is to use 
a disease specific ligand that can be conjugated to a gamma-emitting radio-isotope. 
Cere tecTM is an example of an agent already on the market that has been developed 
by Nycomed-Arnersharn using this principle. Pertechnetate [99fhTc}  is added to a low 
molecular weight ligand to form a complex that can pass through the blood brain 
barrier. When visualised using a gamma camera the compound shows areas of 
ccrch r: 1 
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This technique aids in the d iagnok of stroke. denientia. psychoses. epi leps\ and 
other diseases. Therefore in the first instance the goal of this work has been to aid 
the rational design of a ligand specific to elastase which could be used to image 
elastase-mediated diseases, particularly emphysema. The requirement was for a 
stable elastase inhibitor into which a chemical cage could be incorporated. This 
chemical cage would be capable of chelating 99mTC  for imaging purposes. 13-lactams 
are suicide inhibitors of clastase the reaction of which results in stable covalent 
complexes (Bernstein ci al, 1994). 3-lactams were therefore an ideal starting point 
and work began on 3-lactam compounds with no heavy metal or cage attached. 
Since porcine pancreatic elastase (PPE) is more readily available than human 
leukocyte elastase, PPE has been used as a model for HLE in this study. PPE is 
topologically most similar to HLE (Bode ci al, 1989), the two enzymes sharing 43% 
identity (Bray and Anderson, 1991). The enzymes are especially similar in the active 
site regions. Bode et a! (1989) compared the u.-carbon atoms of the catalytic triad 
and the residues forming the central core of the binding site, finding an r.m.s. 
deviation of only 0.35A. The co-crystal structures of PPE with various 13-lactam 
inhibitors obtained in this work are therefore thought to reflect the binding mode that 
would result in a complex of these inhibitors with HLE. 
1.2. Factor XIII 
Factor Xffl catalyses the last step of the blood clotting cascade. The blood 
coagulation cascade is very complex, involving more than twenty different 
substances (see figure 1.5). The final clot consists of an array of cross-linked fibrin 
that forms an insoluble fibrous network. Fibrin is made from the soluble plasma 
protein, fibrinogen via proteolytic activation by thrombin. Thrombin is synthesised 
as a zymogen, prothrombin. The conversion results from two cleavages by factor X. 
It in turn is activated by the preceding stages in the cascade (Sidelmann et a!, 2000). 
The mechanism by which injury stimulates blood clotting is not yet known. The role 
of factor XIII in coagulation is to stabilise blood clots by cross-linking fibrin 
molecules to protect them from the fibrinolytic enzyme, plasmin (Muszbek et al, 
1996). Factor XIII is a transglutaminase, linking a glutamine from one molecule to a 
lysine from another via E(y-glutamyl)lysyl isopeptide bonds (see figure 1.6) 
(Muszbek et al, 1996). 
Thrombosis is the formation of a blood clot within the blood vessels or the heart. 
The indirect cause is usually some damage to the smooth lining of the blood vessels 
brought about by inflammation or the result of atheroma. (Alexander et a!, 2000). 
Fibrin clots may be gradually broken down by plasmin. However a thrombus may 
persist causing some degree of venous obstruction. In a small proportion of cases a 
fragment of the clot breaks away, forming an embolus. The embolus may travel 
through the venous system, through the right side of the heart and into the pulmonary 
arteries where it becomes lodged. Large thrombi can be devastating, causing sudden 
death in 50% of patients with pulmonary embolism (PE) (Alexander et al, 2000). 
All surgical patients are exposed to a number of risk factors for deep vein thrombosis 
(DVT). This constitutes a significant proportion of the population and any method 
that can help to detect a thrombosis quickly and unequivocally will save many lives. 
Compression ultrasonography is currently the standard first choice of investigating in 
patients with suspected DVT (Wells et al, 2000) but there is potential for false 
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positives and negatives. The latter is particularly an issue for calf vein thrombi so 
repeated testing is needed which is inconvenient and expensive (Wells et al, 2000). 
PE is currently imaged by ventilation-perfusion (V/Q) imaging. This method 
requires the use of two nuclear agents, is time consuming and produces images that 
are difficult to interpret. V/Q imaging is nondiagnostic in most cases (Wells et a!, 
2000). 
Contrast venography is a reference standard for the diagnosis of DVT but is 
expensive and has been relegated to use only in complex and difficult diagnostic 
situations (Baker, 1998). 
It is hoped that the factor Xffl specific radio-ligand will provide a safe, sensitive, 
accurate and accessible method applicable to all types of clots. However this 
depends on the development of a stable ligand to which an imaging modality such as 
99fllTc can be attached. The work on factor XIII described in this thesis was a 
contribution to that aim. 
There are of course many proteins associated with the blood clotting cascade that 
could be considered as a starting point for the design of a thrombus imaging agent. 
However the target had to fulfil the following criteria: 
. The agent had to image both coagulating and lysing clots: peptides are known 
which target active clot formation but not lysing clots. Pulmonary emboli 
however are undergoing thrombolysis, which is why they detach from the leg and 
lodge in the lungs. 
The agent had to image during coagulation treatment: factor Xffl is still active in 
the presence of thrombolytics and anticoagulant whereas factor VII and factor X 
for example are not. 
• The action of factor Xffl allows for multiple incorporation of the label into the 
clot provided that the label is designed as a substrate rather than an inhibitor. 
Apart from its use as a target for medical imaging, factor Xffl is also interesting due 
to its role in haemostasis and in maintaining pregnancy. Homozygous factor XIII 
deficiency typically results in rebleeding after initial clot formation, umbilical and 
intracranial bleeding in children, a 100% spontaneous abortion rate in women and 
sterility in men (Kitchens and Newcomb, 1979). Any new information about its 
biochemistry is therefore useful. 
17 
1.3. Structure Based Drug Design 
1.3.1 General Principles 
Rational drug design refers to the development of therapeutic ligands logically using 
direct or indirect knowledge of the protein with which the ligand interacts. This is an 
iterative process first used in the development of captopril, a therapy for hypertension 
and heart failure (Opie and Kowolik, 1995). In this case the three dimensional 
structure of the target protein (angiotensin converting enzyme) was unknown. 
Biological and biochemical assays were used to compare candidate compounds and 
to make inferences about the ligand binding site which were used to design 
successively improved generations of ligands (Cushman and Ondetti, 1991). 
However a crystal or NMR structure of the protein target is vastly preferable 
especially if the protein is shown in complex with a relevant ligand or "lead 
compound". In this case the process can be termed "structure based drug design" 
(SBDD). The structure of the protein/ligand complex is used to unravel the binding 
mode and conformation of the bound molecule and to indicate the essential 
determinants of the binding affinity. This kind of information is invaluable in 
planning the design of the subsequent generation of ligands. When crystal structures 
of these second generation molecules are analysed new insights are gained for the 
design of the third generation and so on until an extremely high affinity ligand is 
developed (see figure 1.7). Some measure of binding affinity/kinetics is needed to 
produce information in parallel to the structural studies. When results are used 
together in this way, elucidation of the binding behaviour is greatly facilitated. 
The search for drugs against the human immunodeficiency virus type 1 (HIV-l) has 
been a major triumph for structure based drug design. HIV-1 was an entirely 
unknown pathogen when the epidemic emerged in the early 1980's and no existing 
drug was known to be useful against it. The retroviral protease (PR) was quickly 
identified as a potential target for SBDD and the effort was very successful, there 
being now six protease inhibitor drugs in the clinic. X-ray crystallography was in the 
forefront of a co-ordinated approach that involved also NMR, computational studies 
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Figure 1.7: The process of structure based drug design showing the various methods of identifying a 
target protein and lead compound before improving ligand binding by iterative design and testing. 
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and chemical synthesis. The first drug to be developed was a transition state 
analogue, Saquinavir (Invirase) (Wlodawer and Vondrasek, 1998). Another approach 
has been based on the symmetry of the active site. It was thought that symmetrical 
inhibitors would confer specificity for retroviral proteases over mammalian 
homologues. Then Dreyer et al (1998) solved the crystal structure of HIV- I protease 
complexed with a symmetric diol at 2.6 A. The structure showed the symmetric 
inhibitor to bind asymmetrically and the attention turned to asymmetric inhibitors. 
The lead compound was modified to be asymmetrical and eventually Ritonavir 
(Norvir) was arrived at (Wlodawer and Vondrasek, 1998). There is little in the 
literature about the development of Nelfinavir (Viracept) but it seems not to utilize a 
peptidomimetic concept (Wiodawer and Vondrasek, 1998). It was the first PR 
inhibitor to be approved for the treatment of pediatric AIDS. Recent approaches to 
PR inhibitor design have centred around the replacement of a water molecule that has 
been seen tetrahedrally co-ordinated between the enzyme and the inhibitors 
(Wlodawer and Vondrasek, 1998). No such drugs have yet been approved but 
clinical trials are in progress. 
1.3.2 Target Identification. 
As illustrated in figure 1.7, structure based drug design requires a target protein and a 
"lead compound". Usually the target protein is identified before the lead compound 
and there are several ways in which a target may be discovered: 
Since the Renaissance, medical science has sought to describe the disease process 
using a reductionist approach. With the advent of classical biochemistry, this has 
meant an understanding of a given disease in terms of enzymes and substrates, 
receptors and ligands and protein/protein interactions. In this way insulin was 
associated with diabetes by Banting, Best, McLeod and Collip in 1922 (Bliss, 1993), 
thrombin with blood clotting by Schmidt and Morawitz in 1904 (Anonymous, 1966) 
and elastase with emphysema by Turino et al (1969). Equally the biochemical 
investigation of infective agents has identified neuraminidase as a drug target for 
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influenza (Wade, 1997) and -lactamase as a target for drugs to combat antibiotic 
resistant bacteria by (Abraham and Chain, 1940). 
With the modern understanding of genetics, the protein central to the pathology of an 
inherited disease is increasingly discovered after genetic analysis of sufferers has 
identified the faulty gene. For example in this way cystic fibrosis was found to be 
due to an abnormal chloride channel in epithelial cells (Kerem et a!, 1989). 
Genome sequences can be computationally compared to identify highly conserved 
bacterial genes that lack a close human counterpart. This is particularly of relevance 
to the identification of antimicrobial agents. For broad spectrum agents 
bioinformatic analysis of genome sequences can be used to identify proteins that are 
highly conserved in the appropriate range of pathogens associated with for example, 
respiratory infections. This kind of analysis can also uncover proteins of unknown 
function that may be specific to its organism of origin (Dujon, 1996). These provide 
the possibility of antibiotics with a high degree of specificity for that species for 
example Mycobacterium tuberculosis or Helicobacter pylon. Such narrow 
specificity may reduce problems of cross resistance in the future (Rosamond and 
Ailsop, 2000). However there is the limitation that for a protein of unknown function 
it is difficult to screen for inhibitors using a biochemical assay. Any proteins 
identified in this way must be confirmed as essential to its bacterial host by loss-of-
function test (Rosamond and AIlsop, 2000). 
Cell based screening can be an indirect method of target identification. It is 
performed with the intention of discovering biologically active small molecules. 
However once a molecule with the desired biological effect is found, the next step 
may be to find the protein via which it produces its effect. This then allows for the 
possibility of structure based drug design. Cell based screening will be described in 
more detail when high throughput screening is discussed in section 1.3.3. 
1.3.3. Lead Identification 
A lead compound need not have many of the attributes that are desired of a drug. For 
example, a drug needs to have a very high affinity for its protein, perhaps having a Ki 
in the nano- or even pico-molar range. Instead the affinity of a lead compound may 
only be in the milli-molar range. The lead compound is intended as a starting point 
from which the factors determining binding can be elucidated as the initiation of the 
SBDD cycle. 
Analysis of the natural substrate and mechanism of the enzyme can be a useful 
starting point for the design of new therapeutic agents. During enzyme catalysis, 
substrates pass through a "transition-state" before becoming products. Compounds 
that mimic a stable form of the transition-state produced by an enzyme are often good 
inhibitors of that enzyme. Therefore examination of the transition-state can be a 
good starting point in the search for a lead compound. A general drawback of the 
transition-state analogue approach is that whatever binding energy is gained through 
active-site interactions, it is often accompanied by a commensurate loss in specificity 
towards other enzymes that share the same catalytic mechanism. The transition-state 
analogue approach has lead to potent inhibitors of thrombin although lack of 
specificity and poor bioavailability has thus far prevented the successful development 
of these compounds as drugs (Salemme et al, 1997). 
Where screening is employed, docking algorithms have been developed in order to 
reduce the number of compounds to be screened. These algorithms search large 
virtual compound libraries for structures that have the right geometric and electronic 
features to fit the desired binding site. In this way ligands can be scored as to how 
likely they are to bind the target. Algorithms are being designed to accurately model 
the many interactions involved in ligand binding: between ligand, solvent water and 
target protein, while taking into account the flexibility of ligand and receptor 
(Salemme et al, 1997). The free energy changes that accompany the binding of a 
ligand to a macromolecule in water are complex (Salemme et a!, 1997): 
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For the (usually non-covalent) reaction, 
drug + target . 	drug/target complex, 
LG=AH — TAS 
where AG = change in Gibbs free energy 
change in enthalpy 
T = absolute temperature 
AS = change in entropy 
Ligand binding results in a decrease in entropy and therefore requires energy i.e. AG 
must be negative for ligand binding to occur. Energy is gained by the formation of 
hydrogen bonds and Van der Waals interactions. Energy is also gained from the 
displacement of bound water molecules by the ligand since this represents an 
increase in entropy. 
The role of water is a complicating factor since it is essential to ligand binding for 
some proteins. (Rarey et a!, 1999) experimented with incorporating a single water 
molecule during the docking procedure, seeking improved docking scores. The 
improvements seen were minor except in the case of HIV-1 protease for which the 
presence of a particular water molecule is critical. Gane and Dean (2000) raise the 
important point that ligand conformations as found by X-ray crystallography may not 
be a true reflection of their shape in an aqueous environment, especially as most are 
crystallised in organic solvents. It must also be remembered that protein crystal 
structures fail to convey the range of flexibility of which proteins in solution are 
capable. The docking of flexible ligands into flexible proteins is a current challenge 
for designers of docking algorithms (Mangoni et al, 1999). 
High-throughput screening (HTS) is a method for testing large numbers of 
compounds for activity as inhibitors or activators of a particular protein (target based 
screening) or cellular process (cell based screening). 
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HTS requires four elements: (i) suitably arrayed compound libraries; (ii) an assay 
method configured for automation; (iii) a robotics workstation and (iv) a 
computerised system for handling the data. Compounds can be arrayed on chips, on 
beads, on agar plates or more commonly a 96-well microtitre plate (Broach and 
Thorner, 1996). As well as information on potency, a well designed HTS can 
provide information on the specificity of a compound. This can be done by running a 
counter-screen with a related target, for example the serotonin 2A receptor versus the 
serotonin 2C receptor. The more specific the compound the less likely it is to show 
side effects. When similar compounds are run against different targets, past 
performance can give indications about specificity in the current screen. It is 
therefore important that the data collection and management system is flexible 
enough to handle such queries (Broach and Thorner, 1996). 
Cell based assays are an attractive alternative to biochemical assays where it is 
possible to measure the output of a particular cellular process. Downstream 
transcriptional events are particularly amenable to monitoring using reporter genes. 
For example any ligand binding event which leads to the phosphorylation of the 
transcription factor CREB can be quantified by measuring the expression of a 
reporter gene which has an enhancer containing cAMP response elements (CRIEs).' 
The luciferase reporter gene system is an example of one that can be adapted to the 
HTS format (Broach and Thorner, 1996). 
Once a novel bioactive compound has been identified by cell based screening its 
mode of action may or may not be elucidated. One strategy to identify the target is to 
repeat the assay with related derivatives of the lead to determine which modifications 
do not lead to loss of activity. This information is used to construct a 
chromatography resin that selectively extracts the target from cellular extracts. This 
approach was classically used to identify immunophilin and calcineurin as the target 
of the immunosuppressant drugs cyclosporin A and FK506 (Verdine, 1996). It may 
1 CREB recognises and binds to CREs to initiate transcription. 
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not be necessary to identify the target: compounds have been developed using only 
assays and brought to market without ever knowing the target protein. In this way 
Triclosan, an antibacterial agent in many personal care products, was found to inhibit 
the enoyl reductase from Escherichia coli (Parikh et al, 2000). 
Whole cell screening has the advantage that it automatically selects for compounds 
that penetrate cells so problems of bioavailability are less likely to be encountered 
later. The properties of the compound are already established in a context close to 
the normal physiological situation. Whereas in the case of a target based screen in 
vitro activity is less likely to imply in vivo activity. Other advantages of the cell 
based approach are that the starting material i.e. the cells self-replicate avoiding the 
need to purify the target protein. The whole cell method also gives an indication as 
to the cytotoxicity of the compounds. 
A disadvantage of cell based screening is that mammalian cells are difficult and 
expensive to culture in an HTS system. Yeast can be used as an alternative but they 
are surrounded by a cell wall which some compounds may not be able to penetrate so 
potentially useful compounds could be disregarded (Rosamond & AIlsop, 2000). 
Also, target-based screening is more sensitive and easier to perform than cell based 
techniques (Rosamond & Alisop, 2000). It also facilitates rational drug design since 
the target is already associated with the lead compound. 
Combinatorial chemistry is a strategy for the simultaneous production of vast 
numbers of molecules from a set of modular components. As such it is an important 
source of new molecules for use in high throughput screens. Combinatorial 
chemistry has the theoretical potential to generate more diverse molecules than can 
be made. The challenge is to select structural themes to produce a manageable 
number of possibilities. Once a lead is identified, combinatorial techniques can also 
be used for optimisation. Information about the structure-activity relationship can be 
used to direct the process to produce and envelope of analogues around the active 
2.5 
structure (Hogan, 1996). 
The basic chemical requirements for producing combinatorial libraries are: (i) 
reactive complementarity of the building blocks; (ii) the capacity of carry a wide 
variety of functional groups and (iii) non-equivocal reaction pathways (Hogan, 1996). 
The chemical building blocks can be assembled by one of two strategies. By the first 
approach a single coupling chemistry is repeatedly applied to produce oligomers. 
This approach is more amenable to solid-phase synthesis and generally produces 
molecules with flexible backbones. The second approach produces monomeric 
molecules in which multiple variable groups are arranged about a central scaffold or 
core. The scaffold may confer biological activity in itself, in which case varying the 
substituent groups can be a way of refining its properties. Alternatively the scaffold 
may have no inherent biological activity and serves as a spatial framework for the 
display of attached functional groups. In this case the scaffold must be varied to 
sample as many different configurations as possible (Hogan, 1996). Combinatorial 
synthesis can be carried out either in solution or on solid-phase (typically porous 
resin beads). Since the numbers of different compounds are so great, working 
backwards to deduce the structure of any active compound becomes difficult and 
methods for spatially addressing compounds become important. Combinatorial 
libraries can be synthesised in microtitre plates thereby providing addresses for 
particular compounds with the added benefit that the compounds are already arrayed 
for screening. 
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1.3.4. The Future 
As well as the inexorable improvements in computing, many technological advances 
are accelerating the rational design of therapeutic agents. High throughput protein 
structure determination is key to increasing momentum at all stages of the drug 
design process. New classes of crystal or NMR structures are needed to facilitate 
target identification and computational screening as well as the SBDD cycle itself. 
Recently computational analyses of enzyme structures and functions have opened the 
door to the re-engineering of enzyme specificities (Cedrome et al, 2000). 
At a later stage in the development process, non-invasive radiotracer imaging is 
being used to provide high resolution anatomical distributions and localisations of 
radiolabelled drugs. This is being used to generate real time receptor occupancy and 
off-rate studies in humans (Gibson et al, 2000). 
It has to be borne in mind that rational drug design largely fails to address such 
problems as specificity, stability, oral activity, toxicity, cost to manufacture, 
pharmacokinetics, therapeutic window and bioavailability (which involves solubility, 
enzymic degradation, and the ability to cross cell walls or membranes). But these 
problems can at least be addressed with a working knowledge of the structure/activity 
relationship. 
The principles of rational drug design were employed in this work using elastase and 
factor XIII as targets. After an initial structure was obtained of elastase with ligand 
El 116, a combinatorial chemistry approach was taken and the JD260-264 series of 
related inhibitors was synthesised. A third iteration of the structure based drug 
design cycle was initiated with the design and synthesis of JD420. 
With respect to factor Xffl, computer modelling was used to gain insights into the 
binding mode of known peptide ligands in the hope of informing the design of the 
next generation of substrates to which an imaging modality might be attached. 
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Chapter 2: Crystallographic Methods and Results. 
2.1 Crystallisation and Freezing 
2.1.1 Crystallisation methods 
The availability of diffraction quality crystals is the rate limiting step of most 
crystallographic projects. Generally speaking the most important factor determining 
whether a protein can be made to crystallise is purity. A protein must be more than 
98% pure before it can be expected to crystallise. The sample should therefore 
appear as a single electrophoresis band, be monodisperse by light scattering or have a 
well defined mass spectrum. 
The techniques of crystallisation exploit different ways of altering the solubility of 
the molecule. The simplest is evaporation from a volatile solvent, although this is 
more useful for smaller molecules. Temperature change is a method that relies on 
the fact that more solute can be dissolved at higher temperatures to give 
supers aturation. Slow cooling often brings the solute out of solution and into 
crystals. Batch ciystallisation is the oldest and simplest method. Precipitant is added 
directly to the protein solution, bringing about supersaturation and with luck crystals 
will appear (Drenth, 1994). The dialysis method involves placing some protein 
solution in a glass capillary or the cavity of a small plexiglas button, closed off by a 
dialysis membrane. This is then put in a larger volume of liquid in a closed vessel. 
The pH and ionic strength of the exterior solution is varied to find conditions which 
promote crystal growth (McPherson, 1999). 
However the most popular method and the one which has been used in this study is 
that of vapour diffusion, in particular the hanging drop method. A few microlitres of 
protein solution is suspended on the underside of a siliconised glass coverslip. The 
coverslip is inverted over a well of a microtitre plate and sealed down with paraffin. 
The well contains approximately one millilitre of "mother liquor" the constituents of 




Figure 2.1 crystallisation by hanging drop. 
The various techniques of crystallisation all depend on having the protein in a 
supersaturated state see figure 2. 1. In the labile zone centres of nucleation will form 
but the crystals may not grow big. Then the saturation must be reduced to bring the 
system into the metastable zone where the conditions for crystal growth are optimum. 
Otherwise the result may be a miriad of microcrystals which will never grow bigger. 
Often the formation of microcrystals lowers the saturation enough for entry into the 
growth phase (see case b). This is what happens when the batch method is 
successful. However if problems are encountered seeding can be attempted (case c). 
This is the transfer of a microcrystal into fresh mother liquor which is optimised for 
growth rather than nucleation. This can be done by streaking a cats whisker through 
the nucleated solution and then streaking through the fresh drop to transfer the 
microcrystals. The hanging drop method is represented in figure 2.2 by case a). As 
water is lost from the drop by vapour diffusion, the concentration of both protein and 
precipitant increases, bringing the system into the labile zone where nucleation can 
occur. As crystals start to form the metastable zone is entered and the crystals grow. 
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Figure 2.2: Phase diagram showing the relationship between precipitant 
concentration and the concentration of free protein in the crystallisation mixture, 
where a) represents vapour diffusion, b) represents batch technique and c) represents 
seeding. Redrawn from (Brady, 2000). 
2.1.2 Crystallisation conditions 
The first crystallisation of elastase is reported in 1968 (Shotton et al). The protein 
was reported to have been crystallised in Cambridge at 20 °C from a 2% solution of 
elastase in 0.01M sodium acetate pH 5.0 containing 0.02M sodium sulphate. The 
same paper reports the simultaneous crystallisation of elastase in Toronto from a 
0.9% solution in 0.05M sodium citrate pH5.5 by lowering the temperature from 25 to 
20°C. The crystals obtained in both laboratories grew within 2 days and were 
identical. Upon X-ray the crystals were found to be orthorhombic with space group 
P2 1 2 1 2 1 , cell constants a = 51.5 A, b = 58.0 A, c = 75.5 A and contain one elastase 
molecule per asymmetric unit. By 1970, mercury and uranyl derivatives had been 
ciystallised and the three-dimensional structure calculated (Watson et al, 1970) 
(Shotton DM and Watson HC, 1970). 
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For this study crystals of porcine pancreatic elastase (from Calbiochem) were grown 
by the hanging drop method at room temperature. The well solution contained 0.1 M 
sodium acetate buffer at pH 5.1 and 55 mM sodium sulphate. The drops consisted of 
2 p1 of protein at 10mg/mi and 2 .t1 of well solution. Crystals of approximate 
dimensions 0.5 x 0.3 x 0.3 mm grew within four days. The crystals belong to the 
space group P2 1 2 1 2 1 and contain one elastase molecule per asymmetric unit. The cell 
constants for each dataset are as follows: 
Dataset - a b c 
Ell 16 49.976 57.368 74.778 
JD260 50.145 57.928 74.478 
JD261 50.049 57.891 74.612 
JD263 49.987 57.845 74.358 
JD264 50.245 57.856 74.611 
JD420 49.896 57.791 74.405 
AuPEt3 50.262 57.500 74.306 
Re04 50.089 57.777 74.583 
Table 2.1: cell constants in A for each dataset. 	Since the space group is 
orthorhombic, all the angles are 90 ° . 
2.1.3 Cryocrystallography 
Biological molecules are extremely susceptible to radiation damage owing to the 
presence of large amounts of water and the potential for diffusion within the sample 
(Garman and Schneider, 1997). This is a great disadvantage since it is necessary to 
merge data from different crystals so solving this problem would obviate scaling 
problems and result in better quality data (Mitchell and Garman, 1994). By the early 
1990's radiation damage was becoming a limiting problem in the full utilisation of 
newly available synchrotron sources (Garman, 1999). 
Radiation damage is caused largely by 'primary' interactions between the molecules 
in the crystal and the beam. This energy produces heat and breaks the bonds between 
the atoms in the molecules in a dose dependent manner (Garman, 1999). Radicals 
may be produced directly (e.g. damage to the polypeptide) and indirectly (reactive H* 
or OH* produced by destruction of a water molecule). Any thermal energy will 
allow the reactive products to diffuse throughout the crystal causing 'secondary' 
damage which is time- and temperature-dependent. Hass and Rossmann (1970) were 
the first to realise that the most effective way to reduce secondary damage is to 
perform the experiment at low temperatures, at which the reactive products are 
immobilised in the crystal and cannot cause extensive secondary damage. Hass and 
Rossmann (1970) quantified this by comparing the effect of radiation damage on cold 
and room-temperature crystals. They compared the intensities of reference 
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Figure 2.3: The ratio I,/I 0 for two reference reflections plotted as a function of 
exposure time for a typical native (25 °C) and frozen (-75°C) crystal. I represents the 
intensity at time t. Results for 0,0,18 and 10,0,0 are shown with dots and crosses 
respectively (Haas and Rossmann, 1970). 
It can be seen from figure 2.3 that whereas the intensities from room-temperature 
crystals had usually decayed by 10% of their original value within 30 hours, cold 
crystals took more than 300 hours to reach the same point (Haas and Rossmann, 
1970). 
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In recent years it has become routine to flash-cool crystals in liquid nitrogen to near 
100 K greatly extending the crystal lifetime, making it effectively infinite on a home 
source (Henderson, 1990) and significantly prolonging it at the synchrotron (Garman 
and Mitchell, 1996). 
The crystal is transferred to a cryoprotectant solution (usually mother liquor plus an 
antifreeze agent) for a few minutes. The crystal is held by the surface tension of the 
cryo-solution across a loop of very thin nylon and is plunged into liquid nitrogen. 
The presence of antifreeze and the speed of cooling prevents the formation of ice 
which would damage the crystal. Instead, a vitreous glass forms which does not 
affect the diffraction from the crystal. The crystal is bathed in a stream of nitrogen at 
lOOK for as long as it is mounted on the X-ray machine. 
2.1.4 Freezing conditions 
Crystals were soaked in a cryoprotectant solution (well solution containing 30% 
glycerol) for approximately 5 seconds and then flash frozen by immersing in liquid 
nitrogen. 
2.2 Data Collection 
2.2.1. Factors affecting resolution 
Once the crystal is mounted on the X-ray generator the maximum resolution 
detectable is described by the Bragg equation: 
A=2d sin 8 
where X is the wavelength of the incident radiation; d is the smallest resolvable 
distance and 0 is the angle indicated in figure 2.4. Since the resolution achievable 
depends on the angle 0, the closer the detector the higher the resolution detectable 
(see figure 2.4). For the same reason a detector of larger radius will be able to detect 
higher resolution data. 
beam 
resolution spots (edge) 
detector of known radius 
resolution spots (centre) 
Figure 2.4: relationship between crystal to detector distance and maximum detectable 
resolution: the detector which is nearer the crystal (dotted) can collect higher 
resolution. 
The maximum achievable resolution is also dependent on the wavelength of the 
incident radiation such that the smaller the wavelength the smaller the resolvable 
distance. These principles are well demonstrated by analysis of table 2.2 which 
shows wavelength and detector statistics for various X-ray sources. 
Location ) (A) Detector Detector 
Radius(mnz) 
Mi,! c, -rsta/ 





Home 1.54 MAR 300 150 80mm 1.49 A Ip 
Home 1.54 MAR 345 172.5 80mm 1.43A IP 
DL 9.6 0.87 ADSCQ4 90 100mm 1.2A CCD 
DL 14.1 1.488 ADSCQ4 90 70mm 1.69 A CCD 
DL 14.2* 0.97-1.2 ADSC Q4 90 70mm 1.10-1.36 A CCD 
DL 9.5 0.6-1.8 MAR 300 150 120mm 0.69-2.08A IP 
11 11 MAR 165 8.5 75mni 0.74-1.22 A CCD 
DL 7.2 1.488 MAR 300 150 120mm 1.72A IP 
11 
1 
MAR345 172.5 120mm 1.61 A IP 
Table 2.2: wavelength and detector statistics for various X-ray sources demonstrating 
that the most important determinant for highest achievable resolution is the 
wavelength of the incident radiation. 
DL = Daresbury Laboratory 
IP = Image plate 
CCD = Charge coupled device 
* wavelength is slowly tunable 
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2.2.2 Mosaicity and rotation step 
For a perfect crystal the spots will appear as sharp points however crystals are not 
generally absolutely perfect on the molecular level and can be thought of as being 
composed of slightly misaligned minute regions called mosaic blocks (see figure 2.5) 
EIDEXIE10 
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Figure 2.5: Mosaic structure of a crystal 
The greater the degree of the misalignment the greater the size of the spots. 
Increased mosaicity adversely affects the data quality since it increases the number of 
overlaps. Overlapping reflections should be avoided as they will be rejected by the 
integration software. High mosaicity also decreases the signal-to-noise ratio because 
the reflection is more spread out. This usually means that if the mosaicity is 
minimised the diffraction limit is optimised [see (Mitchell and Garman, 1994) where 
this was shown for crystals of phosphorylase b]. It also results in an increase in the 
number of reflections which are not fully recorded on one image. For example a 
reflection with 1.5° mosaicity might be recorded over three consecutive 10  images. 
To obtain the full reflection intensity these images must be scaled together after 




E1116 JD260 JD261 JD263 JD264 JD420 ReO 3ethP 
AuCI 
cocrys cocrys cocrys cocrys cocrys cocrys soak soak soak 
/soak 
res(A) 1.8 1.8 1.6 1.9 1.7 1.8 2.1 1.7 
mos- 0.175- 0.414- 0.191- 0.305- 0.353- 0.285- 0.225- 0.393- 
aicity 0.256 0.718 0.217 0.738 0.498 0.990 0.263 0.524 
Table 2.3: mosaicity ranges of all datasets. All datasets were collected with an 
oscillation of 1.5 ° per image. Plotting resolution limit against mosaicity shows no 
correlation using these data. 
2.3 Data Reduction and quality 
2.3.1 Data Reduction 
The programme Denzo (Otwinowski, 1994a) is used to visualise the frames and to 
index and integrate the diffraction maxima. Denzo automatically locates the 
reflections, determines possible unit cells and calculates what the orientation of the 
cell and the percentage distortion would be if that cell were the true one. The 
operator identifies the cell with the highest symmetry and lowest distortion as the 
true one. From its knowledge of the cell and orientation Denzo then predicts where 
all the spots should fall. The programme then integrates where it expects a 
diffraction maximum to get all the intensities. Denzo also refines the crystal and 
detector parameters eg. the unit cell and missetting angles. An output file is produced 
for each frame listing the Miller index for each spot, its intensity and whether it is 
fully or partially recorded. 
The programme "Scalepack" (Otwinowski, 1994b) is then used to merge the data and 
put all the reflections on the same intensity scale. There are two senses in which the 
data is merged. Firstly the programme finds reflections which are recorded across 
consecutive frames, "partials" and puts the information so it can be treated as one 
reflection. Secondly measurements which are related by space group symmetry and 
which should therefore be the same are compared an average intensity taken and an 
39 
estimated standard deviation (esd) calculated. Scalepack outputs a file listing the 
intensities of each reflection and an esd of that intensity. Scalepack also produces 
statistics about the quality of the data. 
Table 2.4 lists the data collection statistics for all datasets discussed in this work 
including several measures of data quality. It also shows statistics relating to 
refinement and measures of structure quality. 
2.3.2 Measures of Data Quality: 
• Resolution: at medium resolution (around 3A) it is possible to make serious errors 
in the interpretation of the electron-density map. Usually such errors must be 
identified and corrected before the structure will refine properly (Branden and 
Tooze, 1999). At high resolution (around 2A or less) the estimated errors in 
atomic positions are around 0.1-0.2 A provided the amino acid sequence is 
known. Hydrogen bonds can be identified with confidence. (Branden and Tooze, 
1999). 
Completeness: obviously the more data the better. The dataset should be at least 
90% complete. Redundant data can be collected although it may or may not 
reduce the estimated standard deviation for the reflection. 
• Mosaicity: the lower the better, a value of about 0.5 0 is reasonable. 
• R-merge: an internal measure of the accuracy of the dataset. It compares 
differences between symmetry related reflections that should be identical in 
intensity: 
Rrnerg 	I i - II 
where i = the intensity of the reflection 
and I = the mean intensity of all equivalent measurements of the same reflection 
A value of more than 0.30 is unreliable. 
• Sigma II(oI) : the estimated standard deviation of the intensity (I) of a reflection 
which depends on the intensity of the background. JJI is a good indicator of the 
quality of the dataset. A value of less than 3 means the reflection is unreliable. 
LIE 
Table 2.4: Data collection and refinement statistics for all datasets. 
JD264 JD420 AuPEt1 Re04 
1.488 1.488 and 1.5412 1.5412 
1.5412 
1.73 1.80 1.70 2.05 
125,156 229,529 198,708 85,733 
22,979 19,679 24,237 14,063 
3.5 9.2 4.7 12.0 
6.9 4.0 4.0 3.2 
98.5 97.3 99.5 99.1 
18.1 18.2 17.3 16.6 
24.8 27.0 23.5 24.8 
0.007 0.006 0.006 0.005 
0.023 0.022 0.022 0.021 
86.9 87.9 86.2 85.4 
100 100 100 100 
Dataset E1116 JD260 JD261 JD263 
Wavelengh(A) 1.5412 1.5412 1.488 1.5412 
Resolution limit 1.80 1.80 1.60 1.90 
(A) 
Total no. 130,682 123,562 128,575 177,024 
Observations 
Unique 20,396 20,840 27,907 17,317 
Reflections 
Rmerge (%) 6.3 5.2 6.3 12.3 
I/al (last shell) 3.0 5.4 6.3 4.3 
Completeness 99.2 92.8 94.5 97.9 
(%) 
Refinement 
R (.r% .c,, (%), all 16.4 17.4 15.9 17.05 
data 
Rfree, (%), all 22.1 26.1 20.5 25.7 
data 
Root mean square deviation from stereochemical target values: 
Bond Lengths 0.008 0.006 0.009 0.006 
(A) 
Bond Angle 0.022 0.022 0.923 0.021 
Distances (A) 
Ramachandran plane 
Most javoured 86.9 85.9 77.5 86.9 
region (%) 
Additional 100 100 100 100 
allowed (%) 
2.4 Structure Solution and Refinement 
2.4.1. Solving for the ligand by difference map 
All structures discussed in this thesis were refined using the programme Sheixi 
(Sheidrick, 1997). Sheixi uses structure factors (F) so the Scalepack output must be 
converted from intensities (I) to structure factors [I oc  F2]. The observed structure 
factors (IFol) are fed into Sheixi along with an input file describing a model of 
elastase taken from the pdb database. The programme calculates the structure factors 
that would arise from the proposed model (IFcI). Shelxl compares the observed 
structure factors with the structure factors expected from the proposed model (IFcI), 
i.e. it calculates JFoI-FcI. It makes subtle changes to the model, recalculates 
structure factors and compares IFo! and IFcI again and so on for as many cycles as 
instructed. Thus Shelxl fits the model to the data iteratively and eventually outputs a 
slightly better model in pdb format. A difference map is calculated IFoI-IFcI which 
shows areas of electron density which are unaccounted for in the model. In this way 
the electron density for any ligand can be calculated. A model is built of the 
expected ligand and the model is fitted into the difference density. When the ligand 
model has been manually fitted to satisfaction, the model in that orientation is 
incorporated into the Sheixi input file for the whole protein. Shelxl is then instructed 
to refine the appended model against the data. In this work five cycles of refinement 
were usually done. Now a new map is calculated except this time a sigma-weighted 
map is used: 2mIFoI-DIFcI, where m is the figure of merit and D is the resolution-
dependent sigmaa term. The sigma-weighted map is designed to reduce model bias 
and shows electron density around the model as well as showing any differences. 
From this point on refinement involves successive rounds of manual model fitting, 
(including checking all residues, adding waters, discarding waters and improving the 
ligand) and automatic optimisation by Sheixi. Waters were included that had density 
at 1.2cy and which showed H-bonding relationships consistent with a water molecule. 
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2.4.2 Constraints 
For a protein the X-ray data must be fitted to thousands of parameters: x, y and z co-
ordinates for each atom and a temperature factor, which describes the amount of 
thermal motion of the atom. For elastase there are 240 residues and about 250 waters 
which results in about 8500 parameters. For a 1.8 A elastase dataset there will be in 
the order of 18000 data (see table 2.4 for data collection statistics for all datasets). 
This means that there are only two reflections for every parameter which is 
inadequate. This problem is solved by the use of constraints. This means that the 
crystallographer can input into Shelxl what is known of how atoms fit together in a 
protein. In practice this means listing all the bond lengths and bond angles for every 
type of amino acid and for any ligand. 
2.4.3 Measures of Structure Quality 
Refinement programmes are very powerful and unless there is a great deal of data, an 
inaccurate model can be subtly modified until it appears to fit the data better than it 
really does. This effect is called "model bias" and it can mislead the crystallographer 
into giving a bad model more credence than is warranted. The progress of the 
refinement is monitored by the R-factor. The R-factor (R 1 ) is (Jones et al, 1996): 
= 11 IFI - kIFI I 
1F0 1 
(where k is a scale factor to bring F onto the same scale as F 0). 
An R-factor of about 60% indicates that the model does not fit the data better than a 
random distribution of atoms. The R-factor falls as the model is refined and is 
usually below 20% for a well refined structure. 
A small percentage of the reflections (usually 5%) are chosen at random to be 
excluded from the refinement process, and by calculating an R-factor for this 5% 
separately (called the the crystallographer can guard against overfitting the 
data. This is because if the model is close to the truth the 5% of reflections that have 
not been used in fitting will also fit i.e. Rfree  won't be too far from Rc r)st . For example 
the Re might typically be 20-30% when the is 15-25%. Tickle et a! (1998) 
0 
give estimates for the ratio of Rf ee to 	to be expected depending on the 
resolution and completeness of the data. A larger ratio than predicted may indicate 
significant errors in the model while a lower ratio than predicted may indicate that 
the refinement has not reached convergence. The and Rfme  for each dataset 
discussed in this work are given in table 2.4. 
Other indicators of structure quality are temperature factors (or "B values"). High B 
values i.e. over 80 are suspect. Any high B values should be in solvent-exposed 
loops. High B values in the hydrophobic core indicate a problem. 
Due to steric constraints not all phi and psi angles are allowed for most residues 
(glycine having only H as a side chain has the most conformational freedom). A 
Ramachandran plot of phi against psi angles for all the residues in the protein allows 
a quick check of whether the conformational angles are in the allowed regions. Table 
2.4 shows for each dataset the percentage of residues for which phi and psi are 
allowed and favourable. 
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Chapter 3: The Lactarn Ligands. 
3.1 Introduction 
By 1985, a number of small molecule inhibitors of human leukocyte elastase (HLE) 
had been reported. Unfortunately many of these were non-specific inhibitors of other 
serine proteases as well (Knight et al, 1992). Peptide-based inhibitors were more 
specific but lacked oral availability in animals (Knight et a!, 1992). A class of 
cephalosporin derivatives were found to be potent inhibitors of HLE, one of which 
was pharmacologically favourable (Knight et al, 1992). Mechanistic studies by 
Knight et a!, (1992b) indicated that this class of inhibitors was mechanism-based. 
However these cephalosporins were not suitably stable or orally available (Knight et 
a!, 1992b). Simple mono-cyclic f3-Iactams were also found to be mechanism-based 
inhibitors of HLE, but were relatively non-specific, displaying similar potency 
against HLE and cathepsin-G (Knight et al, 1992). Knight et a! (1992) have 
examined the stability and potency of a series of related elastase ligands, L680,833 
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Figure 3.1: diagram of L-680,833. 
This series of inhibitors was found to be extremely stable at physiological 
temperature and pH, the ligands only becoming unstable in base. L-680,833 
resembles very closely a compound that Nycomed-Amersham were investigating as a 
starting point for the design of a new imaging compound for elastase mediated 
diseases. This compound is called El 116 and is shown in figure 3.2. 
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The first mechanism proposed for the reaction of L-680,833 with elastase was 
analogous to the "double-hit" mechanism by which cephalosporins were seen to 
react. This resulted in the covalent attachment of the ligand to both the active site 
serine and histidine (Chabin et a!, 1993). However within months the same group 
had used mass spectrometry to probe the mechanism and concluded that the "double-
hit" was not required to produce a stable 13-lactam-derived HLE-inhibitor complex 
(Knight et al, 1993). Underwood eta! (1995) used mass spectrometry to deduce the 
true mechanism. See figure 3.3 for a diagram of the mechanism of inhibition of 
elastase by 3-lactams such as L-680,833 and El 116. It shows acylation of the 
Ser203, loss of the substituent on C-4 of the lactam ring and subsequent formation of 
the carbinolamine. 
The aim of the work described in this chapter has been to contribute to the 
understanding of how f3-lactams interact with elastase. To that end a crystal structure 
has been calculated of the complex between elastase and Eli 16. Based on the Ell 16 
structure, it was thought that the position 1 functionality determined the interaction of 
the ligand with elastase. A combinatorial chemistry approach was therefore used to 
produce a family of f3-Iactams which varied at position I. These ligands were called 
JD260, JD261, JD263 and JD264 and are pictured in figure 3.2. 3-dimensional 
structures were successfully calculated for each member of the new 13-lactam family. 
LC-MS was performed for each enzyme-iigand complex and this data was used to aid 
the interpretation of electron density maps. 
Examination of the structures of the JD series of ligands with elastase revealed that 
they reacted with elastase by a new mechanism, different from that undergone by 
Ell 16. The JD ligands varied from Eli 16 at position 3, having a hydroxy ethyl group 
instead of a geminal diethyl group. It was the presence of the hydroxy ethyl group 
which conferred the ability to react by the new mechanism. 
Following this discovery a third generation 13-lactam, JD420 was designed (see figure 
3.2). It was thought that the double bond at position 3 would prevent the new 
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mechanism from occurring. Instead it was expected that a "double hit" mechanism 
would be seen, analogous to that seen for cephalosporins. In that case the ligand 
would be bound into the active site by covalent bonds to both the serine and the 
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Figure 3.3: mechanism of inhibition of elastase by beta-lactams such as L-860,833 
(R1CH2COOH and R2CH3) and Eli 16 (Rl=CO-4-rnethyl-pyrazine and R2=Br). 
Based on Underwood et a!, 1995. 
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3.2 Methods 
3.2.1 Co-crystallisations: El 116, JD260, JD261, JD263 and JD264 
The crystals were grown by the hanging drop method at room temperature. Porcine 
pancreatic elastase (Calbiochem) at 10 mg/ml was incubated with a three-fold molar 
excess of inhibitor for 1.5 hours at room temperature before drops were laid. The 
well solution contained 0.1 M sodium acetate buffer at pH 5.1 and 50 MM sodium 
sulphate. The drops consisted of 2 t1 of protein and 2 pi of well solution. Crystals 
of approximate dimensions 0.5 x 0.3 x 0.3 mm grew within four days. The crystals 
belong to the space group P2 1 22 1 and contain one elastase molecule per asymmetic 
unit. See table 2.1 for cell constants. Crystals of the complex were soaked in a 
freezing solution consisting of 30% glycerol and 70% well solution (v/v) for 
approximately 5 seconds and then flash frozen by immersing in liquid nitrogen. 
X-ray data for the Eli 16, JD260 and JD263:elastase crystal complexes were collected 
at lOOK using a MAR300 image plate mounted on an Enraf Nonius rotating anode 
generator operating at 40kV and 80 mA (home source). Data collection statistics are 
given in Chapter 2 table 2.4. X-ray data for the of JD261 and JD 264:elastase 
complexes was collected on station 7.2 at the Daresbury synchrotron source using a 
MAR 300 image plate (see table 2.4 for data collection statistics). 
The structures for Eli 16 and JD261 were solved in the first instance by Dr Paul 
Taylor using the molecular replacement program AMoRe (Navaza, 1994) using the 
model of porcine pancreatic elastase from a published structure (entry 8EST in the 
Brookhaven Protein Database). All water and ligand molecules were removed from 
the model structure. Initial difference Fourier maps using phases calculated from the 
molecular replacement solutions showed clear electron density for both ligands. 
Refinement was carried out using SheIxi (Sheidrick, 1997) (see Chapter 2 table 2.4 
for refinement statistics). All subsequent elastase structures were determined by the 
author using the JD261 model and refined using Shelxl. All structures contained a 
calcium and a sulfate ion as described previously. Despite the short soaking time in 
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the cryoprotectant solution, a well ordered glycerol molecule was located in all the 
complexes. 
3.2.2 Soaking experiment: JD420 
Initial attempts to obtain a crystal structure of JD420 in the active site of elastase 
failed. Attempts were made to co-crystallise the two molecules but upon data 
collection and processing, the active site was found to contain only water molecules 
(data not shown). It was thought that the absence of JD420 in the active site may be 
due to reactivation, in which case any covalent intermediate would be transient. 
Soaking experiments were therefore undertaken in the hopes of capturing a covalent 
intermediate. 
Native crystals were grown as described above except that the elastase was not 
incubated with any ligand before drops were laid. Native crystals were soaked in 
25mM JD420 for 1.5 hours before freezing as described above. X-ray data for the 
complex were collected both at Daresbury station 7.2 and on the home source 
(detailed above). See table 2.1 for the cell dimensions. The data collection and 
refinement statistics are listed in table 2.4. The datasets were merged using 
Scalepack and the structure solved as above. 
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3.3 Results 






/ 	El 116 
The Eli 16 ligand product was clearly visible in the electron density (figure 3.4) 
which showed the presence of both ethyl groups on C-3. The structure refined well, 
Rcryst 16.4 and Rfree = 22.1 the ligand having an average temperature factor of 
10.15A 2 , ranging from 1.52 to 50.07A 2 The refined structure also showed clearly 
that position 4 is tetrahedral with a one atom substituent, consistent with the 
mechanism shown in Figure 3.3. 
There are three hydrogen bonds linking the ligand directly to the protein as shown in 
table 3.1 (below) and in figure 3.5). 
Table 3.1: contacts of Eli 16 
Ligand ser 203 gly 201 gIn 200 his 60 arg 226 hoh ho/i ho/i ho/i 
atom  611 702 751 570 
Lactam H-bond H-bond H-bond 
Carbonyl with N with N 3.13 
(position 2) 2.93+ 3.16  
ears 
(position 3)  
hydroxyl intra- H-bond H-bond 






(position 1)  
urea H-bond 
oxygen  2.89  
distal H-bond 






N- 0 	 moo flT) JD 260 
OH _ V  
S c JO 263 
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The amide nitrogen atoms from G1y201 and Ser203 act as hydrogen bond donors to 
the ester carbonyl oxygen atom which lies in the oxyanion pocket. The NF-2 atom 
from His60 acts as a hydrogen bond donor to the hydroxyl oxygen atom at position 4. 
This hydroxyl group also forms an intra-molecular hydrogen bond to Oy of the active 
site serine. Binding of the ligand is also stabilised by van der Waals interactions with 
Ser222 and Phe223 in binding pocket S2, with Va1224 and G1n200 in binding pocket 
S3 and by a stacking interaction of the aromatic ring with the guanidinium group of 
Arg 226 in binding pocket S4 (see figure 3.5). 
The identity of the acylated enzyme complex has been corroborated by mass 
spectrometry. Figure 3.6 shows the deconvoluted mass spectrum elastase with 
Eli 16. The peak at 25895.6 represents the native enzyme and the major peak at 
26297.7 corresponds to the ligand bound protein. 
3.3.2 JD260, JD261 and JD263. 
Ligands JD260, JD26 1 and JD263 all react with elastase according to the mechanism 
shown in figure 3.7. All the ligands were clearly visible in the initial electron density 
difference maps. The good quality of the refined electron density in each case shows 
that the ligand products are planar between the ester carbon attached to the serine and 
the last nitrogen (Figure 3.8 a-c). Furthermore, there is no trace of substituents on 
positions 3 and 4 of the -lactams. These observations are consistent with the 




Figure 3.6: Deconvoluted electrospray ionisation mass spectrum of 
elastase incubated with 3 fold molar excess Eli 16 for 1 hour. The 
peak at 25895.6 represents the native enzyme and the major peak at 
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The contacts made by JD260, JD261 and JD263 are shown in tables 3.2, 3.3 and 3.4 
respectively (below). 
Table 3.2: contacts of JD260 
Ligand atom ser 203 glv 201 gin 200 his 60 arg 226 cys 199 hoh 750 Izoh 751 
Lactam H-bond H-bond Burgi- 
Carbonyl with N with N Dunitz 
(position 2) 2.66 3.10 approach 
3.23 
(position 3)  
(position 4)  
urea H-bond 
nitrogen 2.78 
(position 1)  





Table 3.3: contacts of JD261 
Ligand atom ser 203 gly 201 gin 200 his 60 arg 226 hoh 759 hoh 750 hoh 751 
Lactarn H-bond H-bond H-bond Burgi- 
Carbonyl with N with N 3.16 Dunitz 
(position 2) 2.75 3.07 approach 
3.30 
(position 3)  
(position 4)  
urea H-bond 
nitrogen 2.95 
(position 1)  





Table 3.4: contacts of JD263 
Ligand ser203 gly2Ol gIn200 his 60 arg226 cvsI99 hoh 750 hoh 751 
atom  
Lactam H-bond H-bond H-bond Burgi- 
Carbonyl with N with N with 0 Dunitz 
(postion 2) 2.77 2.99 3.20 approach 
3.33 
(positon 3)  
(position 4)  
urea H-bond 
nitrogen 3.02 
(position 1)  





As in the Eli 16 structure, the position 2 carbonyls of JD260, JD261 and JD263 make 
hydrogen bonds with the amide nitrogen atoms from G1y201 and Ser203. The planar 
all trans configuration of each ligand product places constraints upon the orientation 
of the urea moiety and only one other direct hydrogen bond can be formed between 
the urea oxygen atom and G1n200 in each case. In all three structures the urea 
nitrogen (position i) is hydrogen bonded to a water molecule that forms a bridging 
hydrogen bond to the amide nitrogen of Va1224. The active site His60 does not make 
any direct hydrogen bonds with any of the three ligands, but does form a hydrogen 
bond to W751in each case (NE2 ... W = 2.7 A). This water molecule is only 3.3 A 
from the carbon of the ester carbonyl and is well positioned to carry out a 
nucleophilic attack along the Burgi-Dunitz trajectory (Figure 3.8a,b,c). The proposed 
mechanism has also been verified by mass spectrometry. Deconvoluted mass spectra 
for each of the complexes are shown in figure 3.9a-c. In each case the major peak is 






Figure 3.9a: Deconvoluted electrospray ionisation mass spectrum of elastase 
incubated with 3 fold molar excess JD260 for one hour. The peak at 26087.1 
represents the covalent product seen in the crystal structure and the smaller peak 
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Figure 3.9b: Deconvoluted electrospray ionisation mass 
spectrum of elastase incubated with 3 fold molar excess 
JD261 for one hour. The major peak at 26132.9 is the 
covalent product seen in the crystal structure. The small 
neighbouring peak at 26179.8 is its precursor which has the 
hydroxyethyl group intact. The 25895.6 peak is the native 
enzyme and the 26399.9 peak represents where the serine has 












Figure 3.9c: Deconvoluted electrospray ionisation mass spectrum 
of elastase incubated with 3 fold molar excess JD263 for one hour. 
The major peak at 26047.7 is the covalent product seen in the 
crystal structure. The small peak at 25935.1 is the same minus the 























Figure 3.9d: Deconvoluted electrospray ionisation mass spectrum of 
elastase incubated with 3 fold molar excess of JD264 for one hour. The 
major peak at 26095.1 is the covalent product seen in the crystal structure. 
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A 1.73A dataset was collected of the elastase JD264 complex at Daresbury (see table 
2.3 for data collection statistics). The initial difference map was unlike those of the 
previous ligand complexes because the JD264 ligand product is disordered over two 
positions. The refinement was very satisfactory, the ligand having an average 
temperature of 24.7A 2 in position A and 21.5A 2 in position B. Temperature factors 
ranged from 5.6 to 39.9A2 and 8.3 to 31.5A2 respectively. The occupancy was 
slightly higher in position B at 0.52 compared with 0.48 in position A. Figure 3. 10 
shows JD264 in both orientations with electron density. As for the rest of the series 
the interpretation of the electron density is consistent with mass spectrometry results 
shown in figure 3.9d. The major ion peak at 26095 can be attributed to the ligand as 
it appears in the electron density and the smaller peak at 25982.9 is the same minus 
the C terminal asparagine. Interestingly neither of the two orientations adopted by 
JD264 are occupied by any of the other ligands examined in this study. 
In position A its contacts are as follows: The serine 203 amide nitrogen is a 
hydrogen bond donor to the lactam carbonyl (2.86A), there is a stabilising H-bond 
between N9 and Gln200 OF-1 (2.55A) and H-bonds to three waters (see table 3.5, 
below). 

Table 3.5: Contacts of JD264 in position A 
Ligand ser 203 gly 201 gIn 200 his 60 ser 222 hoh 935 hoh 920 hoh 758 
atom  
Lactam H-bond H-bond 
Carbonyl with N 2.97 
(position 2) 2.86  
(position 3)  
(position 4)  
urea H-bond H-bond 
nitrogen with 2.85 
(position 1) OI 
2.55  




In position B its contacts are as follows: a hydrogen bond between the ester carbonyl 
both to ser203 N (2.93 A) and to gly 201 N (3.00A) and a favourable hydrogen-it 
cloud interaction between N12 and the imidazole ring of his60 (see table 3.6, below). 
Table 3.6: contacts of JD264 in position B 
Ligand ser 203 gly, 201 gin 200 his 60 ser 222 hoh 935 ho/i 920 hoh 751 
atom  
Lactam H-bond H-bond Burgi- 
Carbonyl with N with N Dunitz 
(position 2) 2.93 2.30 approach 
3.13 
(positon 3)  
(position 4)  
urea 
nitrogen 
(position 1)  
urea 
oxygen  




As in structures of JD 260, JD261 and JD263, water molecule H0H751 is well 
positioned to carry out a nucleophilic attack upon the ester carbonyl carbon of the 
ligand (figure 3.10). 
It can be concluded that ligand JD264 reacts by the same mechanism as the others in 
the series but takes up a different position in the active site. 
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3.3.4 JD420 
The electron density for JD420 is ambiguous and open to interpretation, however the 
fragment shown below has been modelled into the electron density (see figure 3.11). 
HOANANO 
H 	H 
The JD420 fragment appears to lie in a similar orientation to Eli 16 although the urea 
oxygen faces in the opposite direction. The temperature factors of the ligand range 
from 19.8A2 to 48.5A 2. These data would be consistent with the mechanism shown 
in figure 3.12. The contacts are as shown in figure 3.11 and table IT the terminal 
carbonyl acts as a hydrogen bond donor to the backbone oxygen of cys 199 (2.49A). 
The distal nitrogen is hydrogen bonded to the backbone oxygen of ser222 (2.69A). 
There may be a favourable hydrostatic interaction between the ring of the ligand and 
the imidazole of his60. 
Table IT contacts of JD420 
Ligand ser 203 gly 201 gIn 200 his 60 ser 222 CYS 199 hoh 750 hoh 751 
atom  
Lactam H-bond 
Carbonyl with 0 
(position 2)  2.49  
(position 3)  
(position 4)  
urea 
nitrogen 











































Figure 3.12: possible mechanism of reaction of JD420 with elastase. 
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3.4 Discussion and Conclusions 
3.4.1. Mechanism of 3-Lactam Inhibition 
The X-ray structures of the complexes are consistent with the mechanisms outlined 
in Figures 3.3, 3.7 and 3.12. As has been said, the mechanism of reaction of Ell 16 
with elastase is similar to that proposed for L-680,833 binding HLE (Underwood et 
al, 1995). In that work mass spectrometry and NMR were used to show acylation of 
the Ser203, loss of the substituent on C-4 of the lactam ring and subsequent 
formation of the carbinolamine. The work presented here shows that the addition of 
water to the intermediate imine results in a carbon with (S)-configuration - as 
predicted by modelling studies (Underwood et al, 1995). This hydroxyl group on El 
116 forms a hydrogen bond to His60 and may play a role in the reactivation 
mechanism. Indeed this hydroxyl group may be derived from the hydrolytic water 
molecule that is required for deacylation and hence reactivation of elastase. 
The new mechanism revealed by the binding of the JD series of ligands to elastase 
involves initial acylation of Ser203 followed by loss of the OAr group from C-4. 
However, the presence of the hydroxyethyl substituent on C-3 now provides an 
alternative pathway by a retro-aldol reaction to generate the acyl enzyme intermediate 
with release of acetaldehyde. This results in the planar conjugated intermediate 
shown in figure 3.7 and as a consequence there is no possibility of addition of water 
to C-4. The identity of the acylated enzyme complexes have both been verified using 
electrospray ionisation mass spectrometry and the masses of these covalent 
intermediates correspond to the major molecular species. 
The mechanism attributed to JD420 begins in a manner analogous to that of JD260, 
with the opening of the 3-lactam ring and the loss of the position 4 substituents. The 
mechanism could then proceed by the addition of water to the ethene at position 3. 
This would result in a species the same as JD260 which could then undergo the retro-
aldol reaction to release the acetaldehyde. Why the resulting compound would then 
be so vulnerable to reactivation cannot be explained at this time. However attack by 
water on the carbon of the ester carbonyl would result in a fragment which could be 
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represented by the observed electron density. As has been noted from the structures 
of the other JD ligands, there is a water which is well positioned to carry out 
nucleophilic attack on this carbon along the Burgi-Dunitz trajectory. However if 
JD260 and JD420 each pass through a common intermediate in their reactions, they 
would be expected to result in a common product. It could be that the JD420 result is 
an artefact since the structure was obtained from a sample that had been kept in 
solution for an extended period of time and hence, may have decomposed. It could 
also be that the use of soaking rather than co-crystallisation has affected the outcome 
of the experiment. Ideally the starting material would be tested to verify that it has 
the expected chemical structure, however no more sample is available for NMR or 
other testing. In order to resolve the inconsistencies surrounding JD420 the ligand 
has to be re-synthesised and renewed attempts made to obtain a crystal structure of 
the ligand in complex with elastase. Mass spectrometry should also be used to 
corroborate the X-ray findings. Should the results be similar to those reported here, 
being equally ambiguous and inexplicable, the expected fragment could be 
synthesised and soaked into elastase crystals. Electron density similar to that seen in 
the present work would corroborate the interpretation reported here. Work is 
underway to explain the novel behaviour of JD420. 
3.4.2. Comparison of Binding Modes of E1116 and covalent JD ligands with 
Peptide Analogue Compounds 
Atomic co-ordinates are available for 45 other PPE X-ray structures. Protein 
inhibitor:PPE complexes include those with elafin (Tsunemi et a!, 1996), 
chymotrypsin elastase inhibitor (Huang et al, 1994) and -casomorphin-7 (Wilmouth 
et a!, 1997). Small molecule inhibitor complexes include: peptidyl chloromethyl 
ketones (Wei et at, 1988), peptidyl boronic acids (Takahasi et a!, 1989), isocoumarin 
derivatives (Hernandez et a!, 1992), peptidylketobenzoxazoles (Edwards et a!, 1992), 
a peptidomimetic aminimide (Peisach et a!, 1995) and peptidyl fluoromethyl ketones 
(Mattos et a!, 1995). The peptidyl fluoromethyl ketones (see figure 3.13) are of 
particular interest since they adopt a similar binding conformation. In all the 
7 5' 





Tn fluoroacetyl-L-lysyl-L-phenylalanyl-P-isOpropylaflilide (1 elc.pdb). 
F 	CN 
F I H 	 H1 
FO 
H 3 
Trifluoroacetyl-L-lysyl-L-prolyl-isopropy Ian ilide (1 ela.pdb). 
Figure 3.13: peptidyl fluoromethyl ketones of which there are 
crystal structures in complex with elastase. 
aforementioned structures the elastase active site maintains the same shape and 
typical root mean square differences between backbone atoms are less than 0.3 A. 
Essential to catalysis by elastase are the oxyanion hole, which stabilises the 
tetrahedral intermediate, and several subsites for amino acid residues both before (S 
subsites) and after (S' subsites) the scissile bond (Mattos et al, 1995). The portion of 
the peptide substrate remaining in the acyl enzyme intermediate is oriented so that its 
carboxy terminus is closest to the catalytic triad, with the backbone atoms forming an 
antiparallel 13-sheet with the protein, and the side chains occupying the S1-S4 
subsites. Little is known about the S' subsites (Mattos et al, 1994). Figure 3.14 
shows the S 1 -S4 subsites with JD264 and two peptidyl fluoromethyl ketones: TFA-
Lys-Phe-ISO (lelc.pdb) and TFA-Lys-Pro-ISO (lela.pdb). The unique placement of 
JD260, JD261 and JD263 compared to all other published classes of inhibitor gives 
an indication of the relative lack of flexibility caused by their all-trans configuration 
and charge delocalised structure (see figure 3.15). The X-ray structure of 
trifluoroacetyl-Lys-Phe-p-isopropylanilide/PPE defined a new subsite for the anilide 
group which was located under the side chain of G1n200 (Mattos et a!, 1994) (see 
figure 3.14). One ring of the naphthyl group of JD261 partly overlaps this site, but 
the uniquely different conformation of G1n200 in this structure provides a rather 
differently shaped pocket. G1n200 has also moved away to accommodate JD260 and 
JD263, but not as far as for JD261 (see figure 3.15). Arg 226 can also adopt different 
conformations. Generally speaking when the ligand is tucked under G1n200, the Arg 
is pulled in towards the active site. However when the ligand lies between His60 and 
Arg226, the Arg swings away from the active site to accommodate it. Exceptions to 
this are in the structures of JD263 and El 116. In the case of El 116 the ö-i- charge of 
the Arg may be stabilised by an electrostatic interaction with the 6- charge of the 
terminal bromine of the ligand. 
The position of Ell 16 in the active site resembles the binding adopted by other 
peptide-type inhibitors (Bode et a!, 1989) in which the peptide side chains fill the 
specificity pockets S 1 to S4. The closest similarity occurs with the trifluoroacetyl 
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dipeptidyl isopropylanilide family of inhibitors (Mattos eta!, 1995). The Si pocket 
is filled in this family by the TFA group while Eli 16 fills the S  pocket quite 
efficiently with one of the ethyl groups on what was C-3 of the 13-lactam. The S4 
subsite accommodates the aromatic anilide group which lies in the same place as the 
bromophenyl group of Eli 16. 
The main-chain structures of elastase bound to Eli 16 shows an unexpected 
conformational difference from residues Asn99-Thr 100-Asp 101-Aspi 02. All 
available published X-ray structures of PPE complexes show these residues in a type 
I 13-turn. The electron density in the Ell 16 complex clearly shows a 1311 turn despite 
the fact that there are no direct interactions with the ligand which may have induced 
the change (see figure 3.16). 
JD264 is very similar to JD260, the only difference being that JD264 has an extra 
carbon atom between the urea and the ring. It is notable that this addition of just one 
carbon atom has such a profound influence of the position of the iigand in the active 
site. Figure 3.17 shows a model based on JD260 of how JD264 would be positioned 
if it adopted the all-trans conformation of its sister ligands. The modelled JD264 
forms numerous close contacts with the type 111 13-turn formed by Ser225 to Leu227. 
In fact the ring of JD264 would come within 1.66A of the carbonyl carbon of Arg226. 
The need for JD264 to adopt an alternative conformation is therefore apparent. The 
crystal structure shows that it under goes cis/trans isomerisations to put it into either 
of two positions. Either position requires two cis/trans isomerisations compared 
with the standard all-trans configuration so both are equally favourable. 
When in position A it lies in the same space occupied by the proline of 
trifluoroacetyl-L-lysyl-L-prolyl-P-isopropylanil ide (1 ela.pdb). It also partially 
overlaps the side group of Eli 16. While in position B it is accommodated by the S2 




JD420 occupies the same space in the active site as the TFA and lysine of 
trifluoroacetyl-L-lysyl-L-prolyl-P-isopropylanilide (1 ela.pdb). Like the TFA the 
terminal oxygens at position two of the JD420 occupy the Si subsite with the ring 
overlapping the same space as the lysine of the dipeptide. This orientation is also 
similar to that adopted by the Eli 16 from the serine although diverging towards the 
ring (figure 3.15). 
3.4.3. Implications of covalent JD series for Reactivation. 
It has been shown that reactivation of HLE-inhibitor complexes, of a series of 
substituted mono -lactarns, results in a half-life of between 3 and 15 hours. Stability 
of the complex is insensitive to increasing ionic strength and also to the nature of the 
leaving group on C-4, but does however depend on the nature of the substituted urea 
(Green et al, 1995). 
A heptapeptide complexed with elastase (lqix.pdb)(Wilmouth et al, 1997) has been 
found to form an acyl-complex with Ser203 through the C-terminal carboxy group. 
The X-ray crystal structure of this complex shows a water molecule hydrogen bonded 
to NE2 of His60 and in an ideal position to attack the carbon of the ester carbonyl. A 
mechanism has been proposed which explains the cleavage of the acyl-enzyme 
intermediate by a hydroxide ion that is derived by deprotonation of a water molecule 
by His60 (Wilmouth et al, 1997). The structures of JD260, 261, 263 and 264 all 
have an identically positioned water molecule (HOH 751 as shown in figure 3.18). 
However, the presence of the conjugated double bond is likely to make the acyl-
enzyme intermediate stable to hydrolysis. This has been previously noted by the 
inhibition of -lactamase by clavulanic acid (Brown et at, 1996). Further analysis of 
the interesting JD420 result may clarify the requirements for stability to reactivation 
in this system. The covalent JD ligands are therefore examples of a new class of 
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Chapter 4: Elastase and Metals 
Part A: Gold Triethyiphosphine 
4.1: Introduction 
The medicinal use of metals can be traced back to Roman times, when physicians 
first recommended alkaline springs in the treatment of mania. By 1886, Carl Lange 
had been successfully using lithium to treat depression for 20 years (Felber, 1987) 
but the usefulness of lithium for manic depressive illness was only rediscovered in 
1949 by John Cade (Mitchell and Hadzi-Pavlovic, 1999). Bismuth has long been 
used to treat ulcers, being recorded as therapeutic for stomach disease in 1827 
(Anonymous, 1976). Medicinal use of gold and other precious metals was known to 
the Chinese circa 2500 BC (Kean et al, 1997). The Roman physician, Pliny the Elder 
records the use of gold compounds as medicinal agents for multiple ailments 
(Historia Naturalis, book 33). Robert Koch observed that gold cyanide was 
bactericidal to tubercule bacilli in vitro (Kean et al, 1997). So when Dr Jacques 
Forestier (1935) noted the similarity between rheumatoid synovia and tuberculous 
nodules he used gold thiopropanol sodium sulphonate on 15 patients with 
inflammatory rheumatoid disease. His success seeded the subsequent 60 years of 
research into anti-arthritic gold complexes. In more recent years the field has 
developed rapidly. There are several gold drugs currently in use against arthritis, 
Auranofin [Au'(PEt 3) (2,3,4,6-tetra-0-acetyl--D-thioglucose-S)] being the only one 







Auranofin is a "prodrug" i.e. it is rapidly altered in vivo to form the active species. It 
reacts by displacement of the acetlythioglucose (Atg) to leave the gold 
triethyiphosphine (AuPEt 3) bound to the target protein (Shaw, 1999): 
Protein-SH + Et3PAuSAtg 	> Protein-S-Au-PEt3 + AtgSH 
Auranofin reacts with hypochiorite (an oxidant present in inflamed tissues) to give 
triethyiphosphine gold (I) chloride (AuPEt3C1) (Canumalla, 1998) so the biological 
chemistry of this compound is of concern. Like auranofin, AuPEt 3C1 is known to 
react with cysteine sulphurs although it has also been shown to form adducts of 
histidine residues in serum albumin (Xiao and Shaw, 1992). Indeed the only crystal 
structure of a protein with a gold phosphine adduct shows the gold bound to a 
histidine nitrogen (Zou et a!, 2000). The work reported here has resulted in a crystal 
structure of the same adduct in complex with elastase. 
4.2: Methods 
4.2.1: Crystallisation 
The crystals were grown by the hanging drop method at room temperature. The well 
solution contained 0.1M sodium acetate buffer at pH 5.1 and 50 mM sodium 
sulphate. The drops consisted of 2 p.1 of porcine pancreatic elastase (Calbiochem) at 
10 mg/ml and 2p.i of well solution. Crystals of approximate dimensions 0.5 x 0.3 x 
0.3 mm grew within four days. The crystals belong to the space group P2 1 2 1 2 1 with 
cell constants a = 50.262 A, b = 57.500 A, c = 74.306 A and contain one elastase 
molecule per asymmetric unit. 
4.2.2: Soaking and freezing 
Triethylphosphine gold (I) chloride (Et3PAuC1) was dissolved to 3.5 MM in 35% 
MPEG 5000 and 5% DMSO. Crystals were transferred to a 2p.I drop of mother 
liquor and lp.l Et3PAuC1 added. The crystals were incubated for 1.5 hours before 
being soaked in freezing solution consisting of 30% glycerol and 70% well solution 
(v/v) for approximately 5 seconds. Crystals were then flash frozen by immersing in 
liquid nitrogen. 
4.2.3: Data collection 
X-ray data for the crystal complex was collected at lOOK using a MAR300 image 
plate mounted on an Enraf Nonius rotating anode generator operating at 40kV and 80 
mA (home source). The structure was determined using the elastase model from the 
JD261 structure and refined using SHELXL (Sheldrick, 1997) (see Chapter 2 Table 
2.4 for data collection and refinement statistics). The initial difference Fourier map 
using phases calculated from the molecular replacement solution showed clear 
electron density for the gold triethylphosphine. The structure contained a calcium ion 
and a sulfate ion as described previously. Despite the short soaking time in the 
cryoprotectant solution, a well ordered glycerol molecule was located in the complex. 
4.3: Results 
Triethylphosphine gold (I) chloride is known to react with protein by chloride 
displacement resulting in [AuPEt31 forming a covalent bond with a histidine 
nitrogen (Zou et al, 2000). The electron density of elastase soaked with 
triethyiphosphine gold (I) chloride showed the gold triethylphosphine to have two 
alternative positions: on the No and the NE of histidine 75 as shown in figure 4.2 (for 
clarity shown with [4.2a] and without electron density [4.2b]). The ligand attached to 
the NO has an occupancy of 0.735 and the ligand attached to Nc has an occupancy of 
0.265. Glutamate 21 was found to have an alternative position in which it is turned 
away from the minor gold position to allow space for the triethyiphosphine group. 
The relative occupancies of the two orientations of Glu2 1 were refined to correspond 
to the relative occupancies of the two gold triethylphosphine positions. This was also 
done for two alternative orientations of the imidazole ring of His75 which rotates 
slightly such that the gold is close to the plane of the ring in each of its sites. 
Refinement of the two alternative arrangements of the gold triethylphosphine, 
histidine and glutamate was very satisfactory, the temperature factors being as in 
table 4.1. In the major position the contacts are as follows: 3.11A from 
triethyiphosphine C5 to the backbone oxygen of Arg24 and 3.14A from 
triethylphosphine C  to the backbone oxygen of Trp27. In the minor position the 
gold triethyiphosphine has no close contacts. 
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Table 4.1: Temperature factors of histdine 75, 
gluatamate 21 and gold triethyiphosphine in the 
high occupancy (magenta) and low occupancy 
(green) positions. 
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4.4: Discussion and Conclusions 
Gold (I) has a very high affinity for thiolate S and has been said to bind only weakly 
to 0 and N ligands (Guo and Sadler, 1999). However the recently reported crystal 
structure of AuPEt 3CI in complex with cyclophilin showed the AuPEt3 to be bound 
to the nitrogen atom of an active site histidine residue, despite the presence of four 
Cys thiol groups (Zou et a!, 2000). In the elastase structure reported here the AuPEt1 
has also bound to a histidine residue although there are no free cysteines. In the 
cyclophilin structure the single, fully occupied site is at the NE. This is consistent 
with the fact that in cyclophilin the NE is less sterically hindered with respect to the 
rest of the histidine residue and more solvent exposed than N6. However in elastase 
the major site with three quarters occupancy is at the No with the NE site having only 
one quarter occupancy. In elastase NE is hydrogen bonded to 0E2 of glutamate 21. 
By occupying the NF_ site the AuPEt 3 necessitates the movement of glutamate 21 to 
an alternative conformation to avoid steric hindrance. The effect of this is to make 
the NE much less favourable for ligand binding. 
Hydrophobic interactions may also be responsible for making the NO site more 
favourable for gold triethyiphosphine binding in elastase. The three ethyl groups 
occupy a most appropriately sized pocket, (as shown in figure 4.3) the formation of 
which does not require any of the side-chains to adopt unusual positions except 
arginine 24 the carbonyl of which has yielded slightly (see figure 4.4 for comparison 
with El 116 structure). 
It is interesting to speculate on whether in a less sterically hindered environment in 
which there was more solvent exposure, a smaller ligand might show a distribution 
between the E and 0 nitrogens reflective of the distribution of the lone pair on the 
histidine. In this way there is potential to use ligand binding to probe the tautomeric 
states of the histidine. 
It is notable that the AuPEt3 binding site is a very large invagination and it invites 
speculation as to whether it exists for a reason. It could for example be a primordial 
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active site, long since abandoned by evolution in favour of a pocket on the other side 
of the protein, which has become the active site we see today. Although it seems 
very enclosed, mutation of the histidine to glycine or alanine would open the cavity. 
It is an interesting idea that just as there remain in the genome remnants of genes that 
have been abandoned by evolution, so there could remain in proteins remnants of 
active sites. Even more interesting is the potential of this site in terms of protein 
engineering. Recently advances have been made in developing rational strategies 
aimed at reshaping enzyme specificities and mechanisms (Cedrone et a!, 2000). It is 
possible that elastase could be re-engineered for a new task using the 
triethylphosphine binding pocket as a starting point. Enzymes have been re-
engineered before, for example 4-chlorobenzoly-CoA dehalogenase has been 
rationally evolved to a crotonyl hydratase, an activity that is absent from the wild-
type enzyme (Xiang et a!, 1999). Eight residues were changed: two of which were 
catalytic residues. It is notable that both substrate specificity and the mechanism 
were evolved. 
Taken together the crystal structures of gold triethylphosphine in complex with 
cyclophilin and with elastase add to a new understanding of the biological chemistry 
of such compounds as histidine seekers. 
Part B: Perrhenate. 
4.5: Introduction 
As well as therapeutic uses as discussed in part A, metals also have an increasing role 
in diagnostics. The project sponsors design and market ligands which allow the 
targeting of isotopes such as 188Re and 99mTc  for imaging specific diseases. Ceretec 
is one such compound already available in the clinic for cerebral imaging. 
Pertechnetate [99mTC]  is added to a ligand to result in a neutral, lipophilic complex of 
low molecular weight. After intravenous injection the tracer is extracted from the 
blood during its first pass through the brain. The ligand bound 99mTc  readily passes 
intact through the blood-brain barrier and is retained in brain tissue probably due to 
intracellular conversion to a hydrophilic complex. The uptake closely reflects 
regional cerebral blood flow that can then be imaged using a gamma camera to detect 
strokes etc (see chapter 1 section 1.1.3). 
Re shares many chemical properties with Tc (Cotton and Wilkinson, 1980). Like 
99 ''Tc, 186Re emits y  radiation which allows in vitro imaging but it also emits 0 
particles with a half-life of 90 hours making it suitable for radioimmunotherapy (Zhu 
et a!, 1997). The labeling of tumour-seeking monoclonal antibodies with radioactive 
nuclides is now an important method in nuclear medicine for the diagnosis of small 
cancer metastases or for therapy (Kramer et a!, 1998). Attachment of Re to these 
antibodies can be by direct labelling or via a chelating ligand. When used as a direct 
label, Re is typically added as Re0 4 or transchelated from a donor ligand and is 
reported to bind cysteine sulphurs. However there is some confusion about its target 
(Spradau and Katzenellenbogen, 1998) and a complete lack of structural information. 
There are no entries in the Brookhaven Protein Database which contain Re or Tc. 
The long term objective of the project was the development of ligands for elastase 
which could incorporate a cage for the chelation of a metal for medical imaging (see 
chapter 1 section 1.1.3). To this end rhenium was prepared as described in Zhu et al 
(1997) with the aim of making a stable form of Re(V) using sodium glucoheptonate 
as the stabiliser both of the Re(V) and of the SnCI7 which is used to reduce the Re. 
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No ligand was ever successfully co-crystallised with elastase which had a cage 
attached. However the control experiment: the addition of rhenium to elastase in the 
absence of ligand was performed as described in this chapter. As a result the first 




The crystals were grown by the hanging drop method at room temperature. The well 
solution contained 0.1 M sodium acetate buffer at pH 5.1 and 50 mM sodium 
sulphate. The drops consisted of 2 tl of porcine pancreatic elastase (Caibiochem) at 
10 mg/ml and 2 i.t1 of well solution. Crystals of approximate dimensions 0.5 x 0.3 x 
0.3 mm grew within four days. The crystals belong to the space group P2 1 2 1 2 1 with 
cell constants a = 50.089 A, b = 57.777 A, c = 74.583 A and contain one elastase 
molecule per asymmetic unit. 
4.6.2: Soaking and freezing 
100mg of SnC12.2H20 was dissolved in 10il of concentrated HC1 and 2mls of H20 
added. 400mg of sodium glucoheptonate (NaGH) were added to imi of 0.2M acetate 
buffer pH5 and heated in a bath of boiling water to get a clear solution. Smls of the 
NaGH solution were added to 4mls of the SnC12 solution. 0.07g of Re 207 were 
weighed out (144.5llmoles) and dissolved in 2rnls of H 20 and imi of the Sn(GH) 
solution prepared above, to give 48mM rhenium. The solution turned blue to black 
to brown to yellow which suggests that the rhenium was reduced and then oxidised 
again to Re04 (see Cotton and Wilkinson, 1980). 
1.tl of 48 mM Re04 was added to crystals in the 4 p1 drop in which they had grown. 
The crystals were incubated for 1.5 hours before being soaked in a freezing solution 
consisting of 30% glycerol and 70% well solution (v/v) for approximately 5 seconds 
and then flash frozen by immersing in liquid nitrogen. 
4.6.3: Data collection 
X-ray data for the crystal complex was collected at lOOK using a MAR300 image 
plate mounted on an Enraf Nonius rotating anode generator operating at 40kV and 80 
mA (home source). The structure was determined using the elastase model from the 
JD261 structure and refined using SHELXL (Sheldrick, 1997) (see Chapter 2 Table 
2.4 for data collection and refinement statistics). The initial difference Fourier map 
using phases calculated from the molecular replacement solution showed clear 
electron density for the perrhenate. The structure contained a calcium and a sulfate 
ion as described previously. Despite the short soaking time in the cryoprotectant 
solution, a well ordered glycerol molecule was located in the complex. 
4.7: Results 
One perrhenate ion was clearly visible in the initial electron density difference map, 
appearing as a 20 sigma peak. The structure refined satisfactorially, Rcr) st = 16.6 and 
Rfree = 24.8. The refined structure clearly showed the perrhenate to be tetrahedral, 
being co-ordinated to the protein via three of its oxygens (figure 4.5). There are three 
contacts from the 02 of the rhenium: to serine 203 Gy  3.064 A ; serine 203 N 2.743 
A and cysteine 199 0 3.028 A. Perrhenate oxygens 01 and 03 have one contact 
each: 01 to cysteine 199 N 3.021 A and 03 to glutamine 200 N 3.113 A. Oxygen 04 
has no contacts. 
4.8: Discussion and Conclusions 
The crystal structure obtained of elastase soaked with perrhenate clearly shows the 
Re04 ion in the electron density in the active site of the protein. The perrhenate ion 
is sitting in the S 1 subsite of the enzyme, held in place by three hydrogen bonds: 
from the amide nitrogen of serine 203 and the carbonyl oxygen of cysteine 199 and 
from the catalytic serine oxygen. However figure 4.6 showing Connolly surfaces of 
the perrhenate and the surface of the protein shows what a very close fit the 
perrhenate ion is in the S 1 subsite. Such intimate contact must account for what 
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In other available structures, this Si subsite is is occupied by the trifluoroacetyl 
group of trifluoroacetyl-L-lysyl-L-prolyl-P-Isopylanilide (lela in the PDB)(Mattos et 
al, 1994) and by an Xe ion in a structure of elastase under 8 bar Xenon Pressure 
(1dm in the PDB)(Prange et al, 1998). Although both these ligands are also present 
at high occupancy neither fits as closely into the base of the binding pocket. 
Previous attempts to label proteins with Re have centred around strongly reducing 
conditions, both for the metal and for the protein to be labelled (Hnatowich et a!, 
1994; Gooden et a!, 1995; Hnatowich et a!, 1993). Although in this case the elastase 
was in contact with stannous reducing agent, it was clear from the crystal structure 
that none of the disulphide bonds were affected, all remaining intact. Despite contact 
with a reducing agent, it would also seem from the colour changes observed after it 
was added, as well as from the final electron density obtained, that the Re was re-
oxidised by ambient 02 to Re04. This presumably prevented its chelation by 
glucoheptonate. 
This is the first reported crystal structure of a Re adduct to a protein, the Brookhaven 
Structural Database having no entries with a Re or Tc ligand of any sort. To date the 
binding site for Re in proteins has been reported to bind cysteine residues, 
chromatography having been the method used to determine labelling (Hnatowich et 
al, 1994; Gooden et a!, 1995; Hnatowich et a!, 1993; Zhu et a!, 1997). In the work 
reported here the rhenium has not bound to cysteine however this is consistent with 
the fact that the disulphides of the protein have not been reduced. It has previously 
been thought essential to reduce any protein for direct complexing with Re or Tc 
(Hnatowich eta!, 1994; Gooden eta!, 1995; Hnatowich et a!, 1993; Zhu et al, 1997). 
However the work reported here demonstrates that this may not always be necessary. 
Therefore it may be possible, at least in some cases, to label proteins with Re more 
easily than has been thought before. It may also be possible that, since no structural 
analysis has been carried out on any of the previous Re- or Tc- protein complexes, 
Re adducts have previously adopted unexpected binding modes unbeknown to 
investigators. 
(o-. 
The use of chelating agents to label antibodies has certain drawbacks such as the 
expense of synthesis and purification and the danger of immunogenicity when bound 
to the antibody (Gooden, 1995). Schwochau (1994) also notes that 99mTCO4  has 
been successsful compared to metabolisable chelators which can suffer a change in 
their biochemical properties when complexed with a radionucleotide. In a 
comparison of direct and indirect methods of labelling with 99mTc  Hnatowich et a! 
(1993) report that the rate of transchelation to cysteine was 7-20 times higher for the 
direct label (99mTcO4)  and that this led to more rapid clearance from the body since 
conjugation to glutathione and cysteine is an important detoxification mechanism. 
In conclusion the unexpected binding mode for Re0 4 may turn the focus back to 
unconjugated ligands in the development of novel therapeutic and imaging agents. 
1 03 
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Chapter 5: Factor XIII 
Part A: Modelling 
5.1 Introduction 
The aim of this project has been to design high affinity peptide ligands for human 
blood coagulation factor XIII. Such a ligand can then be attached to a radioisotope 
for use as an imaging agent. When injected into a patient, this agent would allow the 
visualisation of blood clots when viewed under a gamma camera. 
5.1.1 Architecture of Factor XIII 
Factor XIII catalyses the last step of the blood clotting cascade. It converts the loose 
mesh work of hydrogen-bonded soluble fibrin into a co-valently bonded polymer, 
which is believed to be more resistant to the action of plasmin than is non-
crosslinked fibrin (Sidelmann et al, 2000). Factor Xffl is a transglutaminase, linking 
a glutamine from one molecule to a lysine from another via e(y-glutamyl)lysyl 
isopeptide bonds (Muszbek et a!, 1996). The a- and y-chains of fibrin are 
crosslinked but not the 13-chains. Antiparallel -y-chains of adjacent fibrin monomers 
are cross-lined quickly by factor Xffla to form y-dimers. a-chain crosslinking 
proceeds more slowly, and the result is the formation of highly cross-linked (X-chain 
polymers (Sidelmann et a!, 2000). The activity of factor XIII can be assayed by 
following the incorporation of a radiolabelled lysyl substrate such as 
dansylcadaverine into a glutamyl substrate such as 13-casein (Cooke, 1974). 
Homozygous factor Xffl deficiency typically results in rebleeding after initial clot 
formation, umbilical and intracranial bleeding in children, a 100% spontaneous 
abortion rate in women and sterility in men (Kitchens and Newcomb, 1979). In 
plasma, factor Xffl exits in the inactive from as a hetero-tetramer, having two A 
subunits and two B subunits. The 13-subunits are inhibitory to factor Xffl catalysis, 
however upon activation the two B subunits fall away and the A-A dimer performs 
the catalysis (Cooke, 1974) (see figure 5.1). 
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Figure 5.1: Diagramatic representation of factor XIII showing the two long thin 
flexible B subunits which fall away upon activation leaving the A-A dimer. Each 
monomer is composed of four domains, barrel 1 (red), core (yellow), barrel 2 (cyan) 
and 3-sandwich (green). 
The B subunits are 75.5kDa and electron microscopy has shown them to be like long 
thin flexible strands which surround the globular A subunits (Carrell et a!, 1989). 
The B subunits are thought to preserve the A subunits in the plasma, protecting them 
against premature activation (Polgar et a!, 1990) and proteolytic breakdown (Mary, 
Achyuthan and Grenberg, 1988). There is also recent evidence that the B subunit 
mediates the interaction of Factor XIII with fibrinogen (Moaddel el a!, 2000). There 
exists a cellular form of the enzyme that is found in platelets and placenta which has 
no B subunits at all and the factor XIII exists only as an A-A dirner (Seelig and Folk, 
1980). 
Figure 5.2 shows a crystal structure of the A-A dirner (determined by Yee eta!: 1FIE 
in the Brookhaven Protein Databank): each monomer is approximately 83kDa and 
has four domains: the 13-sandwich is composed of residues 43-184 (coloured green); 
the core domain is composed of residues 185-515 (coloured yellow); residues 516-
628 are barrel I (red) and residues 629-727 are barrel 2 (cyan). The monomer is a 
triangular wedge shape about I OOA long. The core domain comprises both a-helix 
and 13-sheet, while the other three domains are predominantly 13-sheet. In the active 
site is a catalytic triad of cys-his-asp very similar to the cys-his-asn triad observed in 
cysteine proteases like papain (Yee et a!, 1994). The cysteine (314) sits at the amino 
terminus of the longest helix in the structure, in a cavity bounded by the core and 
(o 
barrel 1 domains (see figure 5.2). 
Factor Xffl works by a charge relay mechanism (Pedersen et a!, 1994) (figure 5.3). It 
shows attack by the sulphur of the active site cysteine on the carbon of the ligand 
glutamine. The interaction of the histidine with the aspartate keeps the proximal 
nitrogen of the histidine positively charged. The positive histidine draws electrons, 
breaking the carbon-nitrogen bond of the glutamine and NH3 leaves. The lone pair 
on the histidine now goes to make the bond with the lysyl substrate and the product 
leaves. 
5.1.2 Activation of Factor XIII 
In the inactive enzyme the 37 amino terminal residues from one monomer cross the 
dimer interface and occlude the active site of the opposite momomer (coloured 
magenta in figure 5.2). The activation process involves the cleavage by thrombin of 
the arg37-gly38 peptide bond to allow the activation peptide to depart (Takahashi, 
Takahashi and Putnam, 1986). However a recent X-ray structure of thrombin cleaved 
factor xm (1FIE in the Brookhaven Protein Databank) showed the activation peptide 
remaining in its original position, still blocking the active site (Yee et a!, 1995). This 
demonstrates that the activation process is very complex and involves multi-factorial 
processes which have not yet been elucidated. 
It is known that apart from thrombin cleavage activation of plasma factor Xffl 
requires calcium ions and the presence of the fibrin substrate (Greenberg, Miraglia et 
a!, 1985). Although the evidence about the activation process is fragmentary and 
sometimes contradictory, certain things seem clear from inspection of crystal 
structure 1FIE: 
• if B subunits are present they must leave 
• the activation peptide must move away from the entrance to the active site (with 
or without thrombin cleavage) 
• a conformational change must occur which moves the barrel 1 domain (coloured 
red in figure 5.2) to unmask the active site. 
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Figure 5.2: ribbon diagram of the A-A dimer of factor XIII levu in the Brookhaven Databank). 
The protein has been cleaved by thrombin but it is still in an inactive conformation. The beta- 
sandwich domains are green (residues 43-184): the core domains are yellow (residues 185-515): 
the barrel I domains are red (residues 516-628) and the barrel 2 domains are cyan (residues 629- 
727). The activation peptides are magenta and can he seen to be cleaved on each monomer (at 
residue 38). The catalytic triad of cys 314. his 373 and asp 396 are represented in spacefilling and 
are coloured purple except for the catalytic sulphurs which are yellow. The calcium ions are orange 
spheres. The pairs of residues having a cis peptide bond are shown in ball and stick representation: 
arg 10 (green)-tyr3 II (cyan): gln425green )-phe426 (cyan) and gly4l Ogreen-pro4 I I (cyan). 
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Figure 5.3: Factor XIII reaction mechanism (after Pedersen et at, 1994). 
The activation of plasma Factor Xffl is accelerated 100 fold by the presence of fibrin 
(Greenberg, Achyuthan and Fenton, 1987). This interaction seems to be mediated by 
the B subunits since no fibrin-induced promotion can be observed in the cellular 
factor Xffl (Greenberg, Achyuthan and Fenton, 1987). Indeed Siebenlist et al (1996) 
have shown that the A 2B 2 tetramer of plasma factor Xffl binds fibrinogen YA/Y  while 
placental factor Xffl, which contains only A chains does not. Small substrates like 
peptides are also known to activate plasma factor XHI (Gorman and Folk, 1981). 
Calcium is the other key regulator of activation. In the presence of physiological 
concentrations of Ca 2 (1.5mM), the B subunits dissociate from thrombin cleaved 
plasma factor Xffl and the active centre thiol group is unmasked generating the 
functional enzyme (Lorand, 1986). However, during prolonged incubation with 
factor XIII, thrombin first activates and then inactivates the enzyme. Inactivation is 
the result of a second cleavage between Lys 513 and Ser 514, resulting in 56 and 24 
kDa fragments. There is disagreement about whether the 56 kDa fragment remains 
active (Muszbek et al, 1999). There is also disagreement about whether Ca 2 can 
prevent degradation at the Lys 513 thrombin site (Muszbek et a!, 1999) (Yee et a!, 
1994). 
There certainly seems to be a role for calcium in the removal of the B subunits from 
the plasma enzyme. While Ca 2,  is required for exposure of the active site thiol group 
in cleaved plasma factor Xffl, exposure of an active site thiol group in cleaved 
platelet factor Xffl which lacks the B subunits does not require Ca 2 (Hornyak and 
Shafer, 1991). Consistent with this analysis is the fact that high levels of Ca 2 (in 
excess of 50mM) can transform plasma factor Xffl from an inactive tetramer to an 
active dimer (de Backer-Royer and Meunier, 1992). 
Cellular factor Xffl is activated slowly by physiological levels of Ca 2 without 
proteolysis. Plasma factor Xffl does not become activated under these conditions and 
the stoichiometric addition of B subunits to cellular factor XIII prevents the 
/1L 
expression of transglutaminase activity in this manner (Polgar et a!, 1990). This 
suggests that one of the physiological functions of the B subunit in plasma factor Xffl 
is to prevent the slow spontaneous activation of the A subunit that would occur in the 
plasma. 
The dissociation of the B subunits from the cleaved plasma enzyme appears to be the 
rate limiting step in the activation, the conformational change which unmasks the 
active centre cysteine being much faster (Lorand, 1986). The dissociated, 
hydrolytically modified A subunit (a') is presumed to have only a fleeting existence 
in the presence of Ca 2' before being transformed into the active species (a*).  In the 
test tube it is possible to mix active A with EDTA to reverse the presumed 
conformational change in that the transamidase activity disappears and that the active 
centre cysteine becomes buried again (Lorand, 1986). However that is not to say that 
such a species would be truly the equivalent of a natural a' molecule. 
Zn2 is very potent in blocking the expression of a*  activity (Lorand, 1986) by 
apparently competing against Ca 2 . The Ca 2' binding site is marked on each 
monomer in figure 5.2. Truncation experiments in which several residues from the 
Asn436 - G1u490 calcium binding site were removed showed a total loss of 
enzymatic activity (Fox et al, 1999). 
Interestingly if Ca 2 is present, only one A subunit needs to be cleaved for both active 
site thiols to be exposed and the enzyme becomes fully active (Hornyak and Shafer, 
1991). This bears out the half-of-the-sites reactivity described by Seelig and Folk in 
1980. 
However, as asserted by Weiss, Metzner and Hilgenfeld (1998) a great deal of energy 
must be required to drive the dissociation of the activation peptide and the separation 
of the barrel I domain from the core domain. They estimate an interaction energy of 
approximately —14kcal/mol between the activation peptide and the protein resulting 
from a total buried surface area of 3700A. There is also a tight interaction between 
II 3 
barrel 1 and the core, with an interaction energy of —1 lkcal/mol or 3000A buried 
surface area. The binding of Ca 2' and fibrin substrate have been implicated in 
triggering the conformational rearrangement necessary to expose the active site. 
However the X-ray structure of the enzyme in the presence of calcium (Fox et a!, 
1999) shows nothing more than small local rearrangements of the calcium-binding 
amino acids, so Ca 2+ alone cannot be responsible for the activation process. If the 
energy for activation is provided by fibrin then one tight interaction will be replaced 
by another and the fibrin would be unable to dissociate. Also, factor XIII is activated 
by small substrates like peptides (Gorman and Folk, 1981), the binding of which will 
not provide such large energies. Based on the X-ray structure of cellular factor Xffl, 
Weiss et a! (1998) propose that cis/trans isomerisation of peptide bonds Arg310-
Tyr3l1, G1n425-Phe426 and Gly4lO-Pro4ll may act as a conformational switch in 
turning the inactive form to the active form. They hypothesise that if one or all of the 
bonds were to isomerise to the energetically favoured trans configuration, local strain 
along the chain would build up which could trigger conformational rearrangement. 
This could result in a reduction in the binding energy between barrel 1 and the core 
domain or even in their partial separation. The remaining energy necessary to expose 
the active site could then be provided by substrate binding. The fact that site-directed 
mutagenesis of Tyr3 11 to alanine completely abolishes enzyme activity (Hettasch 
and Greenberg, 1994) lends credence to this hypothesis. 
In summary then, it can be seen that the mechanism of factor Xffl activation is far 
from clear. In order to further investigate this process an affinity column was made 
for the purification of factor Xffl in its active form, described in Part B. The affinity 
column was to be based on one of the peptide ligands that had been developed by 
Nycomed-Amersham. To aid the design of the affinity column computer modelling 
was employed (described below) to gain an insight into how two high affinity peptide 
ligands might be interacting with the factor XIII. 
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5.2 Methods 
Sybyl v6.3 (Tripos, Inc., 1996) was used to build models of peptide ligands 
developed by Nycomed-Amersham. The molecular modelling programme WitNotP 
(Widmer, 1997) was used to display and manipulate molecules and display maps. 
The crystallographic structure of thrombin cleaved factor Xii was used as a starting 
model, 1FE in the Brookhaven Protein Databank (Yee et a!, 1995). The programme 
Lidaeus (Taylor and Walkinshaw, 1996) was used to calculate volumes on or in the 
factor Xffl where a ligand would experience favourable interaction energy. It does 
this by moving a theoretical probe atom over the surface of the protein and 
calculating the interaction energy between the probe atom and the protein at every 
point, employing an approach first used in the programme GRID (Goodford, 1985). 
Three sets of calculations are used. The first set is done with the probe atom as a 
carbon. Then the programme repeats the process with the probe atom as a hydrogen 
bond acceptor and then as a hydrogen bond donor. The output from Lidaeus is in the 
form of "chicken wire" maps that display volumes of favourable interaction energy. 
The barrel 1 domain was removed from the protein model on the assumption that 
during activation it must be pulled away from the active site as shown in figure 5.4. 
Lidaeus maps were calculated both in the presence and absence of the activation 
peptide since it is not known under what circumstances it departs. Lidaeus maps 
were calculated within a 25A radius of the active site. Maps were coloured for 
simultaneous display as follows: 
• white indicates favourable interaction energy for a carbon (contoured at —I kcal) 
• red indicates favourable interaction energy for a hydrogen bond acceptor 
(contoured at -4kcal) 
• blue indicates favourable interaction energy for a hydrogen bond donor 
(contoured at -4kcal) 
The following peptide ligands were modelled into the Lidaeus maps by eye: 
TT68: Asn-Gln-Glu-Gln-Val-Ser-Pro-Tyr-Thr-Leu-Leu-Lys-Gly 




Ki = 6.3nM Potency = low 
Potency describes the propensity of the ligand to be cross-linked by active factor 
Xffi. Note that this does not correlate directly with the Ki, for example despite 
showing very tight binding, CP25 is not efficiently crosslinked by factor XIII. 
5.3 Results 
Lidaeus maps generated with the activation peptide present can be seen in figure 5.5. 
The N-terminus of the most potent ligand, (TT68) is shown modelled into the maps. 
There is a small pocket for an H-bond donor next to the sulphur of the active site 
cysteine of factor XIII and a similar pocket for an acceptor. When considered with 
the carbon map (see figure 5.5), this constitutes a very plausible binding site for the 
substrate glutamine right next to the catalytic residue. Figure 5.6 shows the N-
terminal portion of TT68 modelled into the Lidaeus maps. It can be seen that 
residues Asn-Gln-Glu-Gln-Val-Ser-Pro occupy the Lidaeus volumes reasonably well. 
The C-terminal portion (residues Tyr-Thr-Leu-Leu-Lys-Gly) fit very poorly (not 
shown). Interestingly the tightest binding ligand, CP25 fitted into the Lidaeus 
volumes much better than TT68 as can be seen in figure 5.7. There are suitable 
pockets for the serine and the lysine that would certainly contribute to the tight 
binding. However there is no orientation that would allow the glutamine access to 
the sulphur of the active site cysteine without sacrificing completely the good fit of 
the rest of the peptide. 
Kinetic data collected by Nycomed-Amersham showed that CP25 has very low 
potency. This means that despite its very tight binding (Ki=6.3nM) this ligand is not 
readily crosslinked by the enzyme. This is consistent in two respects with the model 
of the binding of CP25 to factor Xffl which is presented here. Firstly the model 
might account for the tight binding in that the backbone of the ligand and many of its 
residues have binding sites, suggesting that a comparatively large energy of 





since it places the glutamine too far from the active site residues to be involved in 
catalysis at 6.5 lÀ (figure 5.7). 
In contrast TT68 has the highest potency of all the ligands although it has a 
significantly higher Ki than CP25 (1.41p.M). The model for TT68 binding to factor 
XIII shown in figure 5.5 is consistent with this. The N-terminal residues of TT68 
fitted into the Lidaeus volumes much better than the C-terminal residues of CP25 
fitted into the same volumes. This might explain why CP25 has the lower Ki. It is 
also notable in this model how favourable the orientation of the glutamine of TT68 is 
towards the active site cysteine and how close the 8-carbon of the glutamine comes to 
the catalytic sulphur (see figure 5.8). These characteristics would account for a high 
propensity to being crosslinked. 
Another useful observation is that CP25 binds to factor XIII via its C-terminus 
leaving its N-terminus free and that the opposite is true for TT68 (figure 5.9). 
The model for the glutamine position is also supported by what is known about the 
reaction mechanism. As described in section 5.1. 1 and figure 5.3, the catalysis is 
initiated by attack of the active site cysteine on the carbon of the ligand glutamine. 
The model proposed for the binding of TT68 exhibits a suitably close contact 
between the sulphur of Cys 314 and the carbon of the ligand glutamine (3.8 A) but 
the interaction of the cysteine and His 373 is further than might be expected (5.5 
A)(figure 5.8). However the protein is able to move which presumably brings the 
residues into appropriate range for catalysis. In this respect the model can be said to 
be broadly consistent with the enzyme mechanism. These modelling studies have 
been informed by what is known of the activation process. However, due to the 
extensive conformational changes between the inactive and the active forms of the 
enzyme, it should be noted that any ligand design using the existing crystal structure 
as a starting point is inevitably based on unproven assumptions. Despite this a self 
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Figure 5.9: Ligand CP25 binds factor XIII via the C-terminal. TT68 via the N-
tenninal. 
5.4 Conclusions 
The objective is to design a ligand with the high affinity of CP25 but with a 
correspondingly high potency. As discussed the six C-terminal residues of CP25 
appear to bind well so that sequence should be incorporated in any design. In an 
attempt to bring the glutamine into proximity with the catalytic sulphur, a change in 
chirality was modelled at the serine a-carbon. This did not bring the glutamine any 
closer to the active site cysteine, because if the peptide binds as shown from the 
serine down then the glutamine will always remain at least one bond length short of 
its pocket next to the cysteine. In conclusion then, this model may help to explain the 
poor potency of ligand CP25. 
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Part B: Purification 
5.5 Introduction 
This section describes attempts made to purify and crystallise human blood 
coagulation factor XIII in its active form. The experiment was designed to solve two 
problems at once: the problem of activation and the problem of purification. The 
procedure is outlined in figure 5.10. An affinity column was custom built using a 
derivative of CP25: one of the peptide ligands known to bind factor Xffl. Previous 
studies had identified that CP25 bound tightly to factor Xffl without being 
crosslinked by the enzyme. This was an important property for the ligand to have 
because there was a risk that factor Xffl would bind to the affinity ligand, crosslink it 
to the nearest amino group and leave. A ligand with very high affinity and very low 
potency was therefore ideal. The modelling studies described above indicated that 
CP25 interacted with factor Xffl at the C-terminal end (see figure 5.9) and so a 
derivative of CP25 was constructed which had a cysteine at the N-terminus for 
attachment to thiopropyl sepharose to form the affinity matrix (see figure 5.11). This 
derivative of CP25 is denoted S-CP25 and has the following sequence: 
Cys-Gly-Leu-Glu-Phe-Asp-Thr-Gln-Ser-Lys-Asn-Ile-Leu 
The ligand could be easily released from the sepharose using a reducing agent once 
the factor XIII was bound. The advantage of this approach was three-fold: the 
method promised highly specific purification of factor Xffl; since the peptide was a 
substrate for factor Xffl it was expected to activate the enzyme and it allowed for the 
purification of the ligand bound form of the enzyme directly. Since factor XIII was 
expected only to bind once activated, it was hoped that pure, active, ligand bound 
factor Xffl would result. The starting material for the purification was 
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Figure 5.10: Purification scheme for 





-0-CH7-CHOH-CH 2-S-S-Cys-Gly- Leu-GIu-Phe-Asp-Thr-GIn-Ser-I vs-Asn-Ile-Leu 
thiopropyl 6B sepharose 
Figure 5.11: a derivative of CP25 was constructed with a cysteine at the N-terminal for reversible attachment to thiopropyl 
sepharose while leaving the C-terminal free for factor XIII capture. 
-J 
5.6 Methods 
5.6.1 Purification of Factor XIII 
Attachment of S-CP25 to sepha rose: 
0.02g of thiopropyl sepharose were weighed out and water added dropwise to just 
swell the sepharose. 30pJ were removed and sepharose CL2B (an inert hulking agent) 
was added up to lml. This mixture was washed with buffer A (0. 1M HIEPES + 0.5M 
NaG! pH8). 4.2mg of S-CP25 (2.8.tmoles) were dissolved in 5mls buffer A. This 
was added to the sepharose and tumbled overnight. The sepharose was packed into a 
imi column and washed to baseline with buffer A. 
Removal of HSA fronz fibrogammin®: 
30mls of Affi Blue Gel were equilibrated in buffer A. 4 bottles of fibrogammin (1250 
units from Aventis Behring) were dissolved in 5mls of buffer A and added to the blue 
gel. The mixture was tumbled for 1 hour at 4 °C before centrifugation at 6000 rpm for 
30 mins at 4°C. The supernatant (19mls) was removed and reserved. 2.2mls were 
kept for gels and other tests. 
Thrombin cleavage: 
5 units of thrombin (Sigma) were added to the factor XIII enriched supernatant and 
the mixture tumbled at 37 ° for 15 minutes. The cleavage was halted with the addition 
of 150 imoles benzamidine (0.027g). 
Factor XIII activation/resin binding: 
The thrombin cleaved factor Xffi was combined with the ligand bound sepharose. 




The sepharose/Factor Xffl mixture was poured into a 1 ml column and the liquid 
drawn off at the bottom (the "flow through"). The column was assembled and 
connected and washed to baseline with buffer A. A single peak came off (the 
"wash") 
Elution: 
The column was unpacked and added to 2mls of buffer B (100mM NH4 bicarbonate 
+ 50mM -mercaptoethanol pH 7.9). The mixture was tumbled at 4 °C for 2.5 hours 
before spinning at 6000rpm for 5 minutes to pellet the sepharose. The supernatant 
was removed, aliquoted into ten 200il portions and lyophilised. The sepharose was 
washed by resuspending the pellet in —l4mls buffer A and spinning at 6000rpm for 5 
minutes. The supernatant was discarded. Samples from each stage of the process 
were run on 7.5% minigels (see results section). 
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5.7 Results 
5.7.1. Results of Factor XIII purification 
Figure 5.12: 7.5% minigel of samples from various stages of the protocol, run at 
200V for 55rnins. Bands A and C are factor Xffl A and band B is complement 
protein C3. 
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*50p.l beads were added to lOjil sample buffer and boiled for 5 mins. Samples of 
beads were spun 13000rpm for 5 mins in a microfuge before loading 30tl. 
In all other cases 20pJ sample were added to 5tl sample buffer before boiling and 
20.tl were loaded except where otherwise indicated. 
From the gel it can be seen (lane 2) that most of the starting material is largely human 
serum albumin and that a very significant purification is achieved using the blue gel 
(lane 3). Lane 4 shows that the sample has not been degraded by the thrombin 
treatment. Lane 5 shows no significant bands therefore the majority of the protein 
has bound to the beads. Washing the column with buffer A (inc. 0.5M NaCl) 
dislodges non-specifically bound protein (lane 6). Tumbling the affinity resin with 
50mM -mercaptoethano1 for 2.5 hours fails to elute any significant protein (lane 7). 
Even boiling the beads in sample buffer yields only barely discernable bands of factor 
Xffl and a slightly smaller species (visible in lane 8 of the original gel only). Since 
this protein is not eluted by boiling in sample buffer it can be deduced that it is 
covalently attached to the beads by an unknown process. 
I 2,0 
5.7.2. Control 1 - Identification of the bands. 
To confirm the identity of the important bands on the gel in figure 5.12 (bands 
marked A, B and C), samples seen in lanes 3, 4 and 6 were run on another identical 
gel, and stained with gelcode. The bands indicated with arrows were excised for 
analysis by mass spectrometry. Identification of bands by mass spectrometry was 
performed by Dr. Andrew Cronshaw. Band A was confirmed as Factor XIII A as 
was band C. Band B was identified as complement protein C3. 
5.7.3. Control 2 - Determination of protein bound to beads. 
After the elution process the beads were twice washed with water. 30p1 were 
removed to a 0.2m1 eppendorf and 30tl of Bio-rad protein assay solution were added. 
The solution turned very blue indicating that the protein is associated with the beads. 
30tl of protein assay solution were added to 301.il of fresh CL2B as a control and the 
results were photographed (see figure 5.13) 
5.7.4. Control 3 - To distinguish which beads the protein is stuck to. 
To determine whether the protein is associated with the thiopropyl sepharose or the 
CL213, 140il fresh CL213 was added to 2mls of crude Fibrogammin (reserved after 
Blue gel treatment). The mixture was tumbled at 37 °C for 15mins. CaCl2 was added 
to 140mM (47.9mg) and the mixture was tumbled at 37 °C for 1 hour. The beads 
were spun down (6000rpm for Smins) and the supernatant removed. The beads were 
washed by adding buffer A to 14 mis followed by spinning down and removing the 
supernatant. 0.235m1s buffer B were added to the beads and the mixture tumbled at 
4°C for 2 hours. The beads were spun down and the supernatant removed. The beads 
were washed twice with water. 30p1 were removed to a 0.2m1 eppendorf and 30jil of 
Bio-rad protein assay solution were added. Although some flecs of blue can be seen 
they are not associated with the beads, but form a band above them, being less dense. 
This indicates that in experiment 5.6.1 the protein is associated with the thiopropyl 
sepharose only. 30tl of protein assay solution were added to 30tl of fresh CL2B as a 
control and the results were photographed (see figure 5.13). 
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Figure 5.13: Photograph of beads from control experiments 5.7.3 and 5.7.4: 
-1 L 
"Z" eppendorf: result of 5.7.3 - beads 
from experiment 5.6.1. with Bio-rad 
protein assay solution added - blue colour 
is clearly seen. 
"C" eppendorf: control for 5.7.3 - 
control experiment in which Bio-rad was 
added to fresh CL2B. There is no blue 
colour in the suspension of beads. 
"CL" eppendorf: result of 5.7.4 - 
experiment 5.6.1 was repeated with CL2B 
in the absence of thiopropyl sepharose. 
Blue particles are visible but are not 
associated with the beads, sitting above 
them in a layer of less dense material. 
5.7.5. Control 4 - Attachment and detachment of ligand from thiopropyl 
sepharose. 
0.2g of thiopropyl sepharose were dissolved in water. 30tl were put into a I ml 
column and made up to I ml with CL2B. The column was washed with buffer A 
(0.1M HEPES + 0.5M NaCl pH8) on the gradifrac. 5mg of S-CP25 were dissolved 
in 7mls of buffer A. The column was unpacked and the sepharose added to the S-
CP25. The mixture was tumbled overnight at 4°C. The column was poured again 
and washed with buffer A. I ml of wash was collected. The column was unpacked 
and the sepharose added to 2mls of buffer B (100mM Ammonium bicarbonate + 
50mM 3—mercaptoethanol) before tumbling at 4 °C. The sepharose was centrifuged 
at 6000rpm for 5 mins and the supernatant removed. 
The LCMS was prepared and a Jupiter CS column (Phenomenex) was conditioned. 
The wash sample and a sample of the supernatant were subjected to LCMS. See 
figure 5. 14 a, b and c for details of LCMS and spectra: 
The peptide was vastly more abundant in the supernatant than in the wash proving 













Figure 5.14b: UV spectrum (UV) and relative ion count of 
LCMS from experiment 5.7.5: after the peptide S-CP25 has 
S-CP25 been eluted from the column. The peak corresponding to 
peptide S-CP25 can be seen at 15 minutes approximately, 
15.01 







Attachment of S-CP25 to the thiopropyl sepharose seems successful according to the 
mass spectometry results (5.7.5). Removal of HSA from the fibrogammin using blue 
gel is straight-forward and effective and is well documented in the literature. The 
thrombin cleavage does not appear to unduly degrade the factor Xffl: lane 4 closely 
resembles lane 3 (see figure 5.12). Also a gel was run looking for low molecular 
weight degradation products which were not found (data not shown). The problem 
seems to occur at the factor Xffl activation/resin binding step. It appears that the 
protein is binding in an unexpected fashion which results in a non-reducible covalent 
bond. It is likely that the protein is active at this point indeed it may well be that the 
covalent bond formation is mediated by the active form of the enzyme. Whether the 
protein is being coupled to the affinity ligand, to the spacer or to the matrix of the 
bead itself is unclear. It is notable that the affinity ligand can be eluted on its own 
from the bead by 3-mercaptoethanol but if it is being eluted after factor Xffl binding 
it is not taking the protein with it. It may be that the factor Xffl is aggregating and 
that this process is mediated by its own trans glutaminase activity. So that once a 
factor XIII molecule is crosslinked or otherwise covalently attached to the 
bead/spacer/ligand, it forms a centre of nucleation for aggregation, as other factor 
XIII molecules are crosslinked onto it via free lysines and glutamines on its surface. 
There are certainly many lysines and glutamines exposed on the surface of factor Xffl 
that would be available for such a reaction figure 5.15. This hypothesis might 
explain the fact that in the result of contol experiment 5.7.4, blue flecs are seen which 
are not associated with the beads. These flecs may represent aggregated protein, 
massive enough to escape the washing process. 
In conclusion then, although the experiment described was based on an excellent 
concept, until the problem of self mediated aggregation of factor XIII is addressed the 
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Concluding Remarks 
In summary, the results presented in this thesis are as follows. Crystal structures of 
elastase in complex with various ligands have been obtained. In the case of elastase 
with Eli 16 the structure corroborates a mechanism of inhibition with had been 
previously proposed by Underwood et al,' on the basis of mass spectrometry results. 
In the case of JD260, JD261, JD263 and JD264, the structures reveal a new 
mechanism of inhibition of elastase by -lactams which may be more stable. All the 
above results have been corroborated by mass spectrometry. JD420, a ligand which 
differs from the rest of the JD series by just one atom, has been shown to behave 
unlike any of the others. It has initially reacted like the other 3-lactams but has 
resulted in a non-covalently inhibiting fragment. This observation may be due to 
sample degradation and work continues to resolve this. 
Crystal structures have also been obtained of elastase with perrhenate and 
triethylphosphine gold (I) chloride. Gold triethyiphosphine has been thought to have 
a high affinity for thiolate S. In this work the gold triethylphosphine has been 
refined in two alternative binding modes: to the N8 and the NE of histidine 75. 
Taken together, the crystal structures of gold triethylphosphine in complex with 
cyclophilin 2 and with elastase add to a new understanding of the biological chemistry 
of such compounds as histidine seekers. 
The structure of perrhenate bound snugly into the Si binding site of elastase is the 
first crystal structure of a medically relevant rhenium compound. Like gold 
triethyiphosphine, rhenium compounds were thought to bind proteins via thiolate S. 
The structure reported here suggests that it may be possible to associate rhenium to 
proteins in ways that do not require the strong reducing conditions used to date. This 
'Underwood Di, Green BG, Chabin R, Mills S, Docherty JB, Finke PE, MacCoss M, Shah SK, 
Burgey CS, Dickenson TA, Griffin PR, Lee TE, Swiderek KM, Covey T, Westler WM and Knight 
WB (1995) Biochemistry, 34, pp 14344-14355. 
2 Zou J, Taylor P, Doman J, Robinson SP, Walkinshaw MD and Sadler PJ (2000) Angewandre Cheinie 
International Edition, 39, pp2931 -2934. 
observation could inform the design of new agents for medical imaging and 
therapeutic purposes. 
An ambitious attempt has been made to purify factor XIII in its active form using a 
custom designed affinity column. The technique was not successful as the protein 
seemed to bind the affinity matrix in an unexpected fashion which results in a non-
reducible covalent bond. It is likely that the covalent bond formation is mediated by 
the transglutaminase activity of the active enzyme. Until the problem of self 
mediated aggregation of factor XIII is addressed the purification of this enzyme will 
remain difficult. 
In the absence of a method to obtain a crystal structure of the active form of factor 
XIII, computer modelling was undertaken to aid the design of peptide ligands. This 
modelling was based on the crystal structure of the inactive form of the enzyme. The 
binding of two peptide ligands which had been developed by the sponsors were 
modelled: the most potent one, TT68 and the one with the highest affinity, CP25. 
TT68 fitted into a putative binding site which brought the glutamine into close 
proximity to the catalytic cysteine. CP25 fitted more closely into the putative 
binding site although the glutamine could not be brought into proximity with the 
catalytic cysteine. These observations explained the binding behaviour of the 
peptides seen in kinetic tests by workers at Nycomed-Amersham. With a minor 
alteration: the iodination of a tyrosine to aid blood clearance, TT68 entered phase I 
clinical trials. 
In conclusion, few of the results reported here would have been accurately predicted. 
In this respect these results serve to highlight the important role of X-ray 
crystallography in ligand design. The learning outcome of this work must therefore 
be that even when a result seems predictable it is always valuable to verify it by 
experiment. 
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